

CURRICULUM VITAE

January 01, 2020

PETER W. KALIVAS



Home Address

520 Island Walk West
Mt Pleasant, SC 29464
1-843-991-2627
Email kalivasp@musc.edu

Affiliation

Department of Neuroscience
Medical University of South Carolina
167 Ashley Avenue – BSB 410
Charleston, SC 29425
Tel 843-876-2340
FAX 843-792-4423
Email kalivasp@musc.edu

Education

B.Sc.	1974	Western Washington University, Bellingham (biology)
Ph.D.	1980	University of Washington, Seattle (pharmacology)
Postdoc.	1982	University of North Carolina, Chapel Hill

Professional Experience

1976-1977	Water Chemist, Quilleute Tribal Reservation, La Push, WA
1977-1980	Research Assistant, Department of Pharmacology, University of Washington, Seattle, WA
1980	Instructor, Seattle Community College, Seattle, WA
1980-1982	Postdoctoral Fellow, University of North Carolina, Chapel Hill, NC
1982-1984	Assistant Professor, Pharmacology, Louisiana State University Medical Center, New Orleans, LA
1984-1987	Assistant Professor, Department of Comparative Anatomy, Pharmacology and Physiology, Washington State University, Pullman, WA
1987-1991	Associate Professor, Department of Comparative Anatomy, Pharmacology and Physiology, Washington State University, Pullman, WA

1990-1998	Director, Alcohol and Drug Abuse Program, Washington State University, Pullman, WA
1991-1998	Professor, Department of Comparative Anatomy, Pharmacology and Physiology, Washington State University, Pullman, WA
1995-1996	Visiting Professor, Department of Anatomy and Histology, The Flinders University School of Medicine, Adelaide, SA, Australia
1998-2005	Professor and Chair, Department of Physiology, Medical University of South Carolina, Charleston, SC
2000-2003	Founder and Director, Neuroscience Institute, Medical University of South Carolina, Charleston, SC
2005-2019	Founding Chair, Department of Neuroscience, Medical University of South Carolina, Charleston, SC
2005-present	Distinguished University Professor, Department of Neuroscience, Medical University of South Carolina, Charleston, SC

Students, postdoctoral fellows, visiting scientists

Graduate Students (* MD/PhD)

Name, Date of Degree, Current Affiliation

*Reda Chalhoub, ~2022, MUSC

*Vivian Chioma, 2020, medical student, MUSC

Jasper Heinsbroek, 2018, Assistant Professor, U Colorado School of Medicine, Denver

*Doug Roberts-Wolfe, 2017, Neuroradiology Resident, U Pennsylvania, Philadelphia

Alex Smith, 2015, Postdoctoral Fellow, Mt Sinai School of Medicine, NYC

Michael Stefanik, 2014, Assistant Professor, North Central College, Chicago

*Khaled Moussawi, 2010, Addiction Research Fellow, Johns Hopkins University, Baltimore

*Armina Wiggins, 2010, Neurology Fellow, U Pennsylvania, Philadelphia

Jamie Peters, 2007, Associate Professor, U Colorado School of Medicine, Denver

Megan Moran, 2006, Medical Researcher, Trident Hospital, Charleston, SC

*Mary Lee Gregory, 2006, Pediatric Neurologist, Baltimore, MD

R. Scott Bowers, 2003, Assistant Professor, Psychiatry, Northwestern University

Chad Swanson, 2001, Sr Director Neuro Clin Res, EISAI

Xin-Yun Lu, 1998, Department Chair, Neuroscience, Medical College of Georgia

Ken Bell, 1998, Veterinarian, Spokane, WA

Caryn Striplin, 1996, Researcher, Carolinas Medical Center

Shiouh-Yi Chen, 1996, Professor, Pharmacology, Ming-Yang University, Taiwan

Andrea Bourdelais, 1994, Associate Professor, Psychology, U North Carolina, Wilmington

Roger Dilts, 1992, Lecturer, Kootanai College, Missoula, MT

Mark Austin, 1991, Chair, Biology, Idaho State University, Pocatello

Post-doctoral Fellows

Name, Dates in Lab, Current Title and Affiliation

Ritchy Hodebourg, 2019-present, Postdoctoral Fellow, MUSC

Rusty Nall, 2019-present, Postdoctoral Fellow, MUSC

Brittany Kuhn, 2019-present, Postdoctoral Fellow, MUSC
 Lauren Beloate, 2016-2017, Investigator, St Junes, Memphis, TN
 Anna Kruyer, 2016-present, Postdoctoral Fellow, MUSC
 Daniela Neuhofer, 2015-2020, Research Asst Professor, MUSC
 Constanza Garcia-Keller, 2014-2019, Research Asst Professor, MUSC
 Ana Clara Bobadilla, 2014-2019, Research Asst Professor, MUSC
 Sade Spencer, 2012-2018, Assistant Professor, Neuroscience, University of Minnesota
 Robyn Brown, 2012-2014, Lecturer, Foley Neuroscience Institute, Melbourne, Aus
 Kimberlei Richardson, 2011-2012, Associate Professor, Howard University, Washington DC
 Michael Scofield, 2011-2017, Assistant Professor, Anesthesiology, MUSC
 Cassandra Gipson, 2010-2015, Associate Professor, Psychology, University of Kentucky
 Yonatan Kupchik, 2010-2014, Assistant Professor, Hebrew University, Neurobiology, Jerusalem
 Rachel Smith, 2010-2013, Assistant Professor, Psychology, Texas A&M
 Xiusong Wang, 2009-2011, Assistant Professor, Shandong University, Jinan PRC
 Kathryn Reissner, 2008-2013, Associate Professor, Psychology, University of North Carolina
 Angelica Rocha, 2007-2009, Lecturer, University of the Pacific, Stockton CA.
 Joachim Uys, 2006-2009, Associate Professor, Pharmacology, MUSC
 Mary Torregrossa, 2005-2007, Associate Professor, Neuroscience, University of Pittsburg
 Ryan LaLumiere, 2005-2009, Associate Professor, Psychology, University of Iowa
 Lori Knackstedt, 2005-2009, Associate Professor, Psychology, University of Florida
 Gregory Busse, 2004-2005, Associate Professor, Psychology, American University, DC
 Steven LaRowe, 2004-2005, Associate Professor, Psychiatry, MUSC
 Alejandra Pachionni, 2004-2008, Associate Professor, Universidad National Rosario, Argentina
 Hao-wei Shen, 2004-2008, Professor, Ningbo University, Ningbo PRC
 Nicholas Champieux, 2002-2004, Physician, Paris, France
 Roberto Melendez, 2002-2005, Associate Professor, University of Puerto Rico
 Xing-Chun Tang, 2001-2006, Addiction Psychiatrist, Round Rock, Tx
 Karen Szumlinski, 2000-2005, Professor, Psychology, UC Santa Barbara
 Jiang-Xiang Xi, 2000-2002, Staff Scientist, National Institute of Drug Abuse, Baltimore
 Krista McFarland, 1999-2003, Associate Director, ACADIA Pharmaceuticals, San Diego
 Dave Baker, 1999-2002, Professor and vice-Chair, Marquette University
 Jennifer Cornish, 1997-2000, Professor, Macquarie University, Sydney, Australia
 Behnam Ghazemsadeh, 1996-98, Associate Professor, Marquette University
 Glenda Harris, 1995, Unknown
 Chris Pierce, 1994-1998, Professor of Neuroscience, Rutgers University
 M. Stacey Hooks, 1993-1994, VP of Manufacturing, Alexion Pharmaceuticals, Cheshire, CT
 Mark Klitenick, 1990-1993, Senior Medical Director, Avant Healthcare, NY
 Barbara Sorg, 1990-93, Professor of Veterinary Medicine, Washington State University
 Jeffery Steketee, 1989-92, Professor of Pharmacology, University of Tennessee, Memphis
 Lynn Churchill, 1989-1991, Professor of Vet Medicine, Washington State University (retired)

Visiting Scientists

Name, Dates in Lab, Current Title and Affiliation

Davide Amato, Scientist, 2014, 2018-20 University of Eriangen-Nuremberg, Germany
 Anna Sadakierska-Chudy, Professor, 2017, Polish Academy of Sciences, Krakow, Poland
 Jie Bai, Professor, 2014, Professor, Kunming University, Kunming, China
 Gabriel Quintero, 2010-2011, Associate Investigator, INDICASAT, Panama
 Sam Kombian, Ph.D., 2006, Associate Professor, University of Kuwait, Kuwait City, Kuwait
 Wenhua Zhou, M.D., 2005, 2008, Dean of Medicine, Ningbo University, Ningbo, China
 Richard McGarry, Ph.D., 2004-05, Professor, Appalachian State University, USA
 Liliana Cancellata, Ph.D., 2004-05, Professor, University of Cordoba, Argentina

Michael Bardo, Ph.D., 2002-03, Professor, University of Kentucky, USA
 Luis Alguacil, M.D., 2002-03, Professor and Chair, San Pablo University, Madrid, Spain
 Shigenobu Toda, M.D., 2000-02, Associate Professor, Kanazawa Medical School, Japan
 Mitsu Nakamura, M.D., 1998-99, Associate Professor, Kagawa Medical School, Japan
 Tomohiro Abekawa, M.D., 1998-99, Associate Professor, Hokkaido University, Japan
 Gang Hu, M.D., 1997-98, Chair of Pharmacology, Nanjing Medical University, China
 Mary Urbina, Ph.D., 1996, Associate Professor, Venezuelan Institute of Scientific Investigation, Caracas, Venezuela
 Valerie Dauge, Ph.D., 1991, Professor, Rene Descarte Universite, Paris, France
 Phillipe de Witt, Ph.D., 1990, Professor, University of Belgium, Brussels, Belgium (retired)

Teaching Experience

1977-1980 University of Washington, Seattle
 Teaching Assistant, Pharmacology, College of Pharmacy
 1979 Seattle Community College, Seattle
 Pharmacology Course Director
 1982-1984 Louisiana State University, New Orleans
 Pharmacology Lectures (10 hrs)- School of Medicine
 Pharmacology Lectures (10 hrs)- School of Dentistry
 1984-1998 Washington State University, Pullman
 Course Director, Veterinary Pharmacology
 Course Director, Neuropharmacology (Graduate School)
 Neuroscience Lectures (Undergraduate Neuroscience Major)
 1998-present Medical University of South Carolina, Charleston
 98-03 co-Course Director, Medical Neurosciences
 98-present Lectures (8 hrs), Medical Neurosciences
 02-18 Lectures (4 hrs), Neurosciences I, Graduate School
 09-16 co-direct Graduate Seminar Course- Cognitive Neuroscience
 19-present direct Graduate Seminar Course- Neurobiology of Addiction

Scientific Organizations

College on Problems of Drug Dependence (1996-present)
 American College of Neuropsychopharmacology (1990-present)
 Society for Neuroscience, USA (1985-present)

Grant Review Committee as Member or Chair

1989-1993 Member, Pharmacology Subcommittee, National Institute of Drug Abuse
 1993-1994 Chair, Pharmacology Subcommittee, National Institute of Drug Abuse
 1996-1998 Member, Pharmacology Subcommittee, National Institute of Mental Health
 1997-2000; 2010-2016 Member, Intramural NIDA Review Panel
 1998-2001 Founding Chair, IFCN-1 (now NMB) National Institutes of Health Study Section
 2005-2006 Council Liason to NIDA Intramural Review Board
 2009, 2011, 2014 ad hoc Member, NIDA Centers Review Board

2012-2016	Member, Molecular and Signaling Study Section (MNPS)
2018	NIH Directors Review Panel of NIDA
2018-2021	Member/Chair NURA1 VA Study Section

Editorial Boards

1991-1999	Editorial Board of the <i>Journal of Neurochemistry</i>
1991-2008	Editorial Board of <i>Critical Reviews in Neurobiology</i>
1992-2003	Editorial Board of <i>Synapse</i>
1994-2012	Editorial Advisory Board of <i>JPET</i>
1995-present	Editorial Board of <i>Behavioral Brain Research</i>
1995-present	Editorial Board of <i>Neuropsychopharmacology</i>
1995-2002	Editorial Board of <i>Brain Research</i>
1996-2004	Editorial Board of <i>Neuroscience-Net</i>
1998-2003	Reviewing Editor, <i>Journal of Neuroscience</i>
1999-2002	co-Chief Editor, <i>Critical Reviews in Neurobiology</i>
2000-2004	Editorial Board, <i>American Journal of Psychiatry</i>
2006-2012	co-Chief Editor of <i>Neuropsychopharmacology Reviews</i>
2007-2011	Editorial Board of <i>Molecular Pharmacology</i>
2007-present	Editorial Board of <i>Journal of Biomedical Research</i>
2016-2020	Editorial Board of <i>Personalized Medicine in Psychiatry</i>
2016-present	Editorial Board of <i>Journal of Translational Medicine</i>

Scientific Advisory Boards

2002-07	National Advisory Council on Drug Abuse (NIDA Council)
2003-	Scientific Advisory Board for National Alliance for Research in Schizophrenia and Depression (NARSAD)
2003-	Scientific Advisory Board for Fundacion Cerebro y Mente, Madrid
2003-09	INBRE Scientific Advisory Board, Furman University
2005-07	Chair, Scientific Advisory Board for Medications Development at NIDA
2008-	The Dana Alliance for Brain Initiatives
2010-	Scientific Advisory Board, Promentis, Inc
2013	Chair, Blue Ribbon Panel Review of NIDA Intramural Research Program
2014-	Scientific Advisory Board, Thiolex, Inc
2014-20	Board of Directors, American Brain Coalition

Personal Awards, Fellowships and Named/Plenary Lectures (2010-present)

2010

- Stanley Marsh III Endowed Professorship in Substance Abuse, Texas Tech U, Amarillo, TX
- Plenary Lecture at 13th International Conference on In Vivo Methods, Brussels

2011

- National Plaque of Honor, Ministry of Science & Technology, Panama
- Plenary Lecture at 8th Brazilian Congress of Brain and Emotions, Gramado, Brazil
- Plenary Lecture at Catecholamine Gordon Conference
- Honorary Professor, Ningbo University, Ningbo, PRC
- Member, Fulbright Specialist Roster

2012

- Governor's Award for Excellence in Scientific Research (South Carolina)

- Elizabeth Fitzgerald Sporar Distinguished Lecturer, UT Medical Branch, Galveston
- Senior Visiting Scholar, Fudan University, Shanghai
- Keynote Lecture, Corticostriatal Circuits in Neuropsychiatric Disease, Dallas
- 2012 Rudolf Magnus Lecture, Utrecht, The Netherlands
- 2012 Anniversary Lecture, Universidad Catolica de Chile, Santiago, Chile

2013

- Harry Williams Lecture, Emory University, Atlanta
- Fulbright Senior Specialist, Macquarie University, Sydney, Australia
- Plenary Lecture, Society of Biological Psychiatry, San Francisco
- Plenary Lecture, Recent Advances in Neurosciences, BMRI, Sydney, Australia

2014

- President, American College of Neuropsychopharmacology
- Distinguished Neuroscience Lecture, U Wyoming, Laramie WY

2015

- Cooper Lecture, U Texas, Houston, TX
- Charles R Schuster Memorial Lecture, U Chicago, Chicago, IL
- Meites Lecture, Michigan St University, Lansing, MI

2016

- O'Brien Lecture, U Penn, Philadelphia, PA
- Korean Neuroscience Plenary Lecture, Seoul, Korea
- Presidential Plenary Lecture, ACNP, Hollywood, FL
- Keynote Lecture, ICA Retreat, UCLA, Los Angeles, CA
- Keynote Lecture, SYNAPSE, Clinton, SC

2017

- Keynote Lecture, Intl Behavioral Neuroscience Society, Hiroshima, Japan
- Keynote Lecture, UT Health Science Ctr, San Antonio, TX
- Keynote, University of Michigan/Cayman Chemical, Ann Arbor MI

2018

- Keynote, World Congress on Brain, Behavior and Emotions, Curitiba, Brazil, June 20, 2018

Patents

2005 Moyer JA, Ashton D, Kalivas PW, and Klitenick MA. Combination of a Glycine Transporter (GLYT1) Inhibitor and an Antipsychotic for the Treatment of Symptoms of Schizophrenia as well as its Preparation and Use Thereof. Publication No.: WO2006066121.

2015 Kalivas, PW, K Moussawi and R Malcolm. Composition and methods for reducing addictive behavior. Pending

Record of Research Grants and Awards as PI or co-PI

Previously Funded Grants as PI or co-PI

<u>Date</u>		<i>Total Direct Costs</i>
1980	Washington State Alcohol and Drug Abuse Institute.	\$ 3,448
1980-1982	North Carolina Alcohol Research Authority. Interactions between alcohol and neuropeptides. Co-investigator.	52,388
1980-1982	NRSA Postdoctoral Trainee Award. Neurotensin: Antagonism of dopamine and TRH systems.	37,440
1983-1984	NIMH Small Grant Program. Mesolimbic dopamine and enkephalin lesions	14,990
1983-1984	BRSF, LSU Medical Center. Mesolimbic dopamine produce supersensitivity to enkephalin.	3,700

1984-1986	Scottish Rite Schizophrenia Foundation. Neuropeptide regulation of the mesolimbic dopamine system: Relevance to an amphetamine model of schizophrenia.	38,250
1985-2004	National Institute of Mental Health, R01, Years 1-20. Modulation of mesolimbic dopamine by endogenous compounds.	1,890,313
1986-1989	National Institute of Neurological and Communicative Disorders and Stroke, Years 1-3. Peptides, amines & stress. Project PI on program project.	103,365
1987	National Science Foundation (5,000). National Institutes of Mental Health (10,000) and Drug Abuse (16,200) Private Industry (18,250). Support for NYAS sponsored conference; Mesocorticolimbic Dopamine System.	49,450
1987	Abbott Laboratories. CCK and Dopamine. Prenatal effects of cocaine and stress.	14,000
1987-1990	Washington State Alcohol and Drug Abuse Institute. Role of G proteins and potassium channels in sensitization	41,000
1990-1998	Research Career Development Award (K02), National Institute of Drug Abuse.	648,000
1990-1996	National Institute of Drug Abuse. Enkephalin in the nucleus accumbens Co-PI with Lynn Churchill.	292,000
1991	National Institute of Alcoholism and Alcohol Abuse. (3,000) Private Industry (15,000). Support for NYAS sponsored conference. Neurobiology of Alcohol and Drug Abuse.	18,000
1992	Spokane Inland Northwest Community Fund	1,200
1993-1994	ACEA Pharmaceuticals. Glycine agonists	10,543
1996	Fogarty Fellowship for Sabbatical (Flinders Med Ctr; Australia)	17,500
1997	Computer Animation for Pharmacology Instruction	1,900
1999-2010	National Institute of Alcohol Abuse and Alcoholism, P50, Project #4. Pharmacotherapeutics for multiple relapse, Co-I	300,000
1999-2012	National Institute of Drug Abuse. R01, NAC-1 a cocaine regulated mRNA in rat brain. Subcontract with Scott Mackler	725,000
2000-2001	Johnson and Johnson, Topiramate and craving	25,979
2000-2003	National Science Foundation. EPSCoR Neuroscience Center	1,400,000
2000-2005	Jansen, Glycine transport antagonists	420,000
2001-2004	National Science Foundation Undergraduate training in neuroscience	123,000
2002-2003	Vertex Pharmaceuticals, Inc	37,000
2003-2008	National Institute of Alcohol Abuse and Alcoholism, Multiple relapse to alcohol: effects on gene expression. Co-PI	1,000,000
2003-2018	National Institute of Drug Abuse. P50 NIDA Center, Years 1-15, (Kalivas, PI)	12,500,000
2005-2008	CV Therapeutics, Palo Alto, CA Adenosine receptors and addiction	175,000
2005-2009	National Institute of Drug Abuse. RO1, Neurobiology of stress induced reinstatement in cocaine addiction.	375,000
2006-2011	National Institute of Drug Abuse. P20 NIDA Translational Center (PI of Project 1; Ron See overall PI)	400,000
2009-2011	National Institute of Drug Abuse. P30 Tenure-Track Faculty Development (PI; faculty target Arthur Riegel)	920,000
2009-2012	National Institute of Alcoholism and Alcohol Abuse. P30 Tenure-Track Faculty Development (PI; target faculty Patrick Mulholland)	780,000
2012-2014	Department of Defense, NAC in PTSD (Kalivas, PI)	450,000
2015-2019	National Science Foundation. EPSCoR. (Kalivas PI)	2,400,000
2015-2020	National Institute of Drug Abuse. RO1 (Froeliger, Gray, Kalivas PIs)	2,100,000
2016	NIDA Travel Grant: 6 th Annual Aspen Brain Forum (Kalivas PI)	25,000

2016-2017	Department of Defense, NAC in PTSD (Kalivas, PI)	302,000
2018	Conference funding for Addiction School in Nairobi. IBRO (Kalivas, co-I)	22,000
2018-2019	National Institute of Drug Abuse, Supplement to R01 (Kalivas, PI)	100,000
2018-2019	Apintyx, Inc	75,000

Active Research Grant Support as PI or co-PI

<u>Date</u>		<u>Total Direct Costs</u>
1984-2020	National Institute of Drug Abuse, R01, Years 1-36. Opioids and cocaine in drug abuse. (Kalivas PI)(NCE)	4,135,807
2000-2025	National Institute of Drug Abuse. R01, Years 1-25 and craving for cocaine (Kalivas PI)	5,100,000
2018-2023	National Institute of Drug Abuse, U01 (Kalivas signing PI, multiPI)	3,500,000
2018-2022	National Institute of Drug Abuse, U54 (McRae PI, Kalivas Project PI)	1,000,000
2018-2022	Veteran's Administration Merit Award (Kalivas, PI)	900,000
2019-2024	National Institute of Drug Abuse, P50 NIDA Center (Kalivas, PI)	6,800,000

Record of Research Grants and Awards as Sponsoring Mentor

Previously Funded Mentored Grants as Sponsor

1990-1992	NRSA Postdoctoral Trainee Award (Sponsor for Mark Klitenick).	41,000
1991-1993	NRSA Predoctoral Trainee Award (Sponsor for Caryn Striplin).	23,000
1992-1994	NRSA Postdoctoral Trainee Award (Sponsor for Stacy Hooks).	42,000
1993-1996	NRSA Postdoctoral Trainee Award (Sponsor for R. Chris Pierce).	65,000
1994-1997	NRSA Predoctoral Trainee Award (Sponsor for Ken Bell)	35,000
1999-2001	NRSA Predoctoral Trainee Award (Sponsor for Chad Swanson)	40,000
1999-2002	NRSA Postdoctoral Trainee Award (Sponsor for Krista McFarland).	93,000
1999-2002	NRSA Postdoctoral Trainee Award (Sponsor for David Baker)	62,000
2001-2004	Canadian Medical Research Institute Postdoctoral Training Grant (Sponsor for Karen Szumlinski)	63,000
2001-2003	NASA Predoctoral Trainee Award (Sponsor for Scott Bowers)	34,000
2002-2004	Phillip Morris Postdoctoral Fellowship (Sponsor for Nicholas Champtiue)	90,000
2003-2006	NRSA Predoctoral Trainee Award (Sponsor for MaryLee Gregory)	60,000
2004-2005	NRSA Postdoctoral Trainee Award (Sponsor for Steve LaRowe)	55,000
2004-2005	NIDA INVEST Award (Sponsor for Lilia Canceled)	55,000
2005-2006	NRSA Predoctoral Trainee Award (Sponsor for Megan Moran)	60,000
2005-2009	NIMH K23 (co-Sponsor for Ziad Nahas)	500,000
2005-2007	NRSA Predoctoral Trainee Award (Sponsor for Jaime Peters)	60,000
2006-2008	NRSA Postdoctoral Trainee Award (Sponsor for Lori Knackstedt)	80,000
2007-2008	NIDA INVEST Award (Sponsor for Wenhua Zhou)	55,000
2007-2009	NRSA Postdoctoral Trainee Award (Sponsor for Ryan LaLumiere)	80,000
2008-2011	NIDA KO1 (Sponsor for Art Riegel)	330,000
2008-2011	MD/PhD NIDA NRSA (Sponsor for Armina Wiggins)	68,000
2009-2010	ARRA NIDA supplement support for summer students	70,000
2008-2011	NRSA Postdoctoral Trainee Award (Sponsor for Kate Reissner)	80,000
2011-2013	NRSA Postdoctoral Trainee Award (Sponsor for Rachel Smith)	80,000
2011-2016	KO1 NIDA Early Career Development Award (Mentor for Kimberlei Richardson)	500,000
2012-2013	K99 Postdoctoral Trainee Award (Sponsor for Kate Reissner)	250,000
2012-2013	NRSA Postdoctoral Trainee Award (Sponsor for Cassie Gipson)	45,000
2014-2016	NRSA Postdoctoral Trainee Award (Sponsor for Sade Spencer)	90,000
2014-2015	Fyssen Award (Sponsor for Ana Clara Bobadilla)	40,000

2014-2016	K99 Postdoctoral Trainee Award (Sponsor for Cassie Gipson)	250,000
2014-2016	KO1 NIDA Early Career Development Award (Mentor for Angie Cason)	500,000
2014-2016	HHMI Minority Career Development (Sponsor for Sade Spencer)	50,000
2015-2017	NRSA MD/PhD Trainee Award (Sponsor for Doug Roberts-Wolfe)	55,000
2015-2017	K99 Career Development (Sponsor for Mike Scofield)	250,000
2016-2018	K99 Career Development (Sponsor for Sade Spencer)	250,000
2014-2019	KO1 NIDA Early Career Development Award (Mentor for Jamie Peters)	500,000
2017-2018	F32 Postdoctoral NIDA NRSA (Sponsor for Anna Kruyer)	60,000
2018-2020	NRSA MD/PhD Trainee Award (Sponsor for Vivian Chioma)	55,000
2019-2020	K99 Career Development (Sponsor for Ana Clara Bobadilla)	250,000

Active Mentored Grants as Primary Sponsor

2017-2020	Deutsche Forschungsgemeinschaft Visiting Scientist Award (Sponsor for Davide Amato)	100,000
2019-2023	K99 Career Development (Sponsor for Coti Garcia-Keller)	250,000
2020-2022	NRSA MD/PhD Trainee Award (Sponsor for Reda Chalhoub)	55,000

Conferences Organized

IUPS Satellite Symposium, Peptidergic and aminergic actions and their interactions, Pullman, WA, July 20-22, 1986.

New York Academy of Sciences, Mesocorticolimbic dopamine system, Miami, FL, May 4-6, 1987.

Sensitization: Biochemical, Physiological and Behavioral Perspectives, Pullman, WA, Spring, 1987.

The Basal Forebrain: Anatomy to Function, Chicago, IL, March 24-27, 1990.

The New York Academy of Sciences, The Neurobiology of Drug and Alcohol Addiction, Spokane, WA, July 23-26, 1991.

Mesolimbic Locomotor Circuit and its Role in Neuropsychiatric Disorders, Pullman, WA, Spring, 1992.

6th Annual Aspen Brain Forum, The Addicted Brain and New Treatment Frontiers, New York, NY, May 18-20, 2016.

The Brain Addicted to Heroin and Opioids and How to Treat It, Salisbury, NC, November 7-9, 2017.

Drugs of Abuse: Neurobiology, Neurochemistry, Behavior and Cognitive Effects, IBRO sponsored school, Nairobi, Kenya, July 7-10, 2018.

Using Intrusive Thinking to Develop Treatments for Neuropsychiatry, Frankfurt, Germany, June, 2019.

The Neurobiology of Drug Addiction, IBRO sponsored school, Rabat, Morocco, March 14-22, 2020

Invited Presentations at Conferences, Academic Institutions, Government Agencies and Pharmaceutical Companies (2010-present)

- Keynote Speaker, UCLA Addictions Consortium, Los Angeles, CA, February 10, 2010
- The Salk Institute for Biological Studies, La Jolla, CA, March 4, 2010
- Marsh Endowed Lectureship in Substance Abuse, Amarillo, Tx, March 10, 2010
- American Psychiatric Association, New Orleans, May 26, 2010
- Translational Research in Methamphetamine Addiction Conference, Pray, MT, July 20, 2010
- Plenary Lecture, 13th Intl Conference on In Vivo Methods, Brussels, Belgium, Sept 14, 2010
- Psychiatry 60th Anniversary Celebration, Univ Maryland, Baltimore, MD, Sept 16, 2010

- Psychiatry Grand Rounds, Columbia University, New York, NY, Oct 1, 2010
- Aquitaine Addiction Conference, Bordeaux, France, Oct 13, 2010
- Faculty, IBRO-sponsored Neuroscience School, Durban, South Africa, Oct 28-29, 2010
- African Neuroscience Society, Durban, South Africa, Oct 30, 2010
- American College of Neuropsychopharmacology, Boca Raton, FL, Dec 6-7, 2010
- Scripps Institute, Jupiter, FL, Feb 18, 2011
- Department of Neuroscience, Tufts University, Boston, MA, March 2, 2011
- Neuroscience Symposium, University of Minnesota, Minneapolis, MN, April 29, 2011
- Psychiatry Grand Rounds, University of Miami, FL, May 4, 2011
- Drug Discovery Problems for Brain Disorders, Panama City, Panama, May 30-31, 2011
- 8th Brazilian Congress of Brain, Behavior and Emotions, Gramado, Brazil, June 14-17, 2011
- Plenary Speaker, Catecholamine Gordon Research Conference, Maine, August 7, 2011
- Molecular Biology of Addiction, Cold Spring Harbor, NY, August 13, 2011.
- Sino-American Symposium on Drug Addiction, Ningbo, CN, September 9-11, 2011
- Biological basis of mental functions, 32nd Naito Conf, Yamanashi, Japan, Oct 18-21, 2011.
- American College of Neuropsychopharmacology, Hawaii, Dec 7, 2011.
- Department of Neuroscience, U Connecticut, Hartford, January 31, 2012
- Department of Neuroscience, U Alabama, Birmingham, March 8, 2012
- Keynote, Cortical Circuits in Neuropsychiatric Disorders, UT Dallas, TX, April 13, 2012.
- Psychiatry Grand Rounds, U Arkansas, Little Rock AR, April 19, 2012
- Faculty Lecture, NSAS: Addictive Disorders, San Quirico d'Orcia, Italy, May 16-17
- Elizabeth Fitzgerald Sporar Distinguished Lecturer, UTMB, Galveston, TX, June 1, 2012
- Senior Visiting Scholar Lecture, Fudan University, Shanghai, China, June 6, 2012
- Plenary Speaker, Dept Neurosciences, U So California, Los Angeles, CA, Sept 30, 2012
- 50th Anniversary Plenary Speaker, Universidad de Catolico, Santiago, Chile, Oct 4, 2012
- Rudolf Magnus Lecture, Utrecht, The Netherlands, Nov 06, 2012
- Harry Williams Lecture, Dept Pharmacology, Emory University, Atlanta, Jan 29, 2013.
- Department of Neuroscience, Vanderbilt University, Nashville, March 6, 2013.
- Lecturer, FENS-IBRO Neuroscience School, Bertinoro, Italy, March 28, 2013.
- Institute of Cellular & Molecular Biology, University of Texas, Austin, May 9, 2013.
- Plenary Lecture, Society of Biological Psychiatry, San Francisco, May 17, 2013.
- Molecular Biology of Addiction, Cold Spring Harbor, NY, August 11, 2013.
- Department of Pharmacology, U New South Wales, Sydney, September 06, 2013.
- Neuroscience Research Workshop, Macquarie University, Sydney, September 09, 2013.
- Recent Advances in Neuroscience, Brain & Mind Research Institute, Sydney, Sept 13, 2013
- Neuroscience Seminar, Florey Institute, Melbourne, September 18, 2013
- Nebraska Neuroscience Symposium, Omaha, October 3, 2013.
- McClean Hospital, Boston MA, October 29, 2013
- American College of Neuropsychopharmacology, Hollywood FL, Dec 10, 2013.
- Department of Physiology and Neuroscience, U So Carolina, Columbia SC, Feb 3, 2014
- Gallo Institute, UCSF, San Francisco CA, Feb 27, 2014
- World Congress of Brain, Behavior and Emotions, April 8, 2014
- Distinguished Neuroscience Lecture, U Wyoming, Laramie WY, April 24, 2014.
- Hotchkiss Brain Institute, U Calgary, Calgary Alberta, May 2, 2014.
- Plenary Lecturer, Ross University Research Day, Dominica, May 23, 2014.
- In vivo Monitoring Molecules, Los Angeles, August 05, 2014.
- Department of Psychiatry, Mayo Clinic, Rochester MN, September 05, 2014
- NIDA Drug Target Development, Bethesda, DC, September 09, 2014
- 8th Metabotropic Glutamate Receptor Conference, Taormina Sicily, September 30, 2014
- Wofford College, Spartanburg SC, October 22, 2014
- Cooper Lecture, Department of Psychiatry, U Texas, Houston TX, February 25, 2015
- Grand Rounds, Department of Psychiatry, U Wisconsin, Madison WI, March 13, 2015
- Department of Integrative Physiol Neuro, Washington St U, Pullman, WA April 24, 2015
- Department Neuroscience, U Pittsburg, Pittsburg, PA May 4, 2015

- Grand Rounds, Department of Psychiatry, U Chicago, Chicago, IL May 14, 2015
- Maise Lecture, Department of Physiology, Michigan St U, East Lansing, MI Oct 3, 2015
- Dept of Neuroscience, University of Mississippi, Jackson, MS Nov 3, 2015
- American College of Neuropsychopharmacology, Hollywood FL, Dec 10, 2015.
- University of Puerto Rico, San Juan PR, Jan 15, 2016.
- Addiction Seminar, NIDA Intramural Research Program, Baltimore MD, Feb 19, 2016.
- Dept of Neuroscience, University of Minnesota, Minneapolis, MN, March 7, 2016
- O'Brien Lecture, University of Pennsylvania, Philadelphia, PA, March 30, 2016
- Keynote Lecture, SYNAPSE, Clinton, SC, April 2, 2016
- Integrative Neuroscience Research Ctr, Marquette University, Milwaukee, WI, April 12, 2016
- Emotions Lecture Series, University of Wisconsin, Madison, WI, April 19, 2016
- Keynote Lecture, ICA Retreat, UCLA, Los Angeles, CA, May 9, 2016
- Herrenhausen Symposium on Psychiatric Disorders, Hanover, Germany, May 12-14, 2016
- 6th Aspen Brain Forum: Neurobiology of Addiction, New York, NY, May 19, 2016
- Addictive Disorders Lecture, NSAS, Cortona, Italy, June 5, 2016
- College of International Neuropsychopharmacology, Seoul, Korea, July 5, 2016
- Plenary Lecture, Society for Korean Neuroscience, Seoul, Korea, September, 29, 2016
- Presidential Plenary Lecture, ACNP, Hollywood, FL, Dec 5, 2016
- Department of Neuroscience, UT San Antonio, TX, Feb 9, 2017
- Department of Neuroscience, Johns Hopkins Medicine, Baltimore, MD, Feb 23, 2017
- Alcohol Center, UNC, Chapel Hill, NC, March 14, 2017
- 12th Intl Basal Ganglia Society, Merida, Mexico, March 28, 2017
- Department of Neuroscience, U Utah, Salt Lake City, UT, April 18, 2017
- Grand Rounds, Department of Psychiatry, U Utah, Salt Lake City, UT, April 19, 2017
- Plenary Lecture, UT Health Science Ctr, San Antonio, TX, May 5, 2017
- 72nd Society of Biological Psychiatry, San Diego, CA, May 18, 2017
- Keynote Lecture, Intl Behavioral Neuroscience Society, Hiroshima, Japan, June 28, 2017
- Neurobiology of Drug Addiction Gordon Conference, Hong Kong, PRC, July 18, 2017
- Faculty Lecture, Cold Spring Harbor Laboratories, Addiction Neurobiology, Aug 9, 2017
- Keynote, University of Michigan/Cayman Chemical, Ann Arbor MI, Sept 7, 2017
- Research Institute on Addictions, SUNY Buffalo, Buffalo NY, Sept 8, 2017
- 9th Metabotropic Glutamate Receptor Conference, Taormina Sicily, Oct 2, 2017
- Department of Physiology, Northwestern University, Chicago IL, Nov 2, 2017
- Neuroscience Institute, Florida Atlantic University, Jupiter FL, Feb 20, 2018
- Neuroscience Congressional Caucus, April 11, 2018
- Sigma Xi Banquet Key Note, April 19, 2018
- Neuroscience lecture, Karolinska Institute, Stockholm, Sweden, May 24, 2018
- Center for Social and Affective Neuroscience, Linkoping, Sweden, May 25, 2018
- Keynote, World Congress on Brain, Behavior and Emotions, Curitiba, Brazil, June 20, 2018
- Faculty Lecturer, IBRO School on Addiction Biology, Nairobi, Kenya, July 7, 2018
- Lecture, Neurobiology of Addiction, University Cordoba, Cordoba, Argentina, Oct 22, 2018
- ISN, Neurobiology of Addiction, Cordoba, Argentina, Oct 24, 2018
- ACNP Session Chair, Hollywood, FL, Dec 12, 2018
- New Perspectives on Opioid Treatment, NIDA, Bethesda, Feb 08, 2019
- Lecture, Department of Anesthesiology, University of Colorado, Denver, March 19, 2019
- Neuroscience Graduate Lecture, University of Minnesota, Minneapolis, March 25, 2019
- Strungmann Forum, Frankfurt, Germany, June 15-20, 2019
- FEBs Symposium, Krakow, Poland, July 11, 2019
- CSHL Neurobiology of Addiction, Lloyd Harbor, August 7, 2019
- Grand Rounds, Laureate Institute, Tulsa, Oklahoma, November 19, 2019
- ACNP Session Chair, Orlando, FL, Dec 08, 2019
- ACNP Panel Presenter, Orlando, FL, Dec 09, 2019
- Grand Rounds, Marcus Autism Center, Atlanta, GA, Jan 24, 2020

- Neuroscience Seminar, Mt Sinai School of Medicine, March 06, 2020

PUBLICATIONS

Books/Volumes Edited

1. *Mesocorticolimbic Dopamine System.* P.W. Kalivas and C.B. Nemeroff, eds. Ann. N.Y. Acad. Sci., Vol. 537, 1988.
2. *Sensitization in the Nervous System.* P.W. Kalivas and C.D. Barnes, eds. Telford Press, New Jersey, 1988.
3. *The Basal Forebrain: Anatomy to Function.* T.C. Napier, P.W. Kalivas and I. Hanin, eds. Plenum Press, 1991.
4. *The Neurobiology of Drug and Alcohol Addiction.* P.W. Kalivas and H. Samson, eds. Ann. N.Y. Acad. Sci., Vol 654, 1992.
5. *Limbic Motor Circuit in Neuropsychiatry.* P.W. Kalivas and C.D. Barnes, eds. CRC Press, Boca Raton, 1993.
6. *Neuroplasticity: A new window on therapeutics in psychiatric disease.* PW Kalivas & H Manji, eds, Nature Publishing, Vol 39, 2008.
7. *Role of Corticostriatal Circuits in Addiction.* G Aston-Jones, PW Kalivas, J McGinty, CM Reichel and A Riegel, eds, Brain Research, Vol 1628, 2015
8. *Intrusive Thinking, From Molecules to Free Will.* PW Kalivas and M Paulus, eds., MIT Press, in press, 2020

Refereed Publications of Original Research or Reviews

1. Kalivas, P.W. and A. Horita. 1979. Thyrotropin-releasing hormone: Central site of action in antagonism of pentobarbital narcosis. *Nature* 278: 461-463.
2. Kalivas, P.W. and A. Horita. 1980. Thyrotropin-releasing hormone: Neurogenesis of actions in the pentobarbital narcotized rat. *J. Pharmacol. Exp. Ther.* 212: 203-210.
3. Kalivas, P.W. and A. Horita. 1980. Response to intracerebral administration of cerebrospinal fluid in the pentobarbital pretreated rat. *Neuropharmacology* 19: 497-499.
4. Kalivas, P.W., L.M. Halpern and A. Horita. 1980. Synchronization of hippocampal and cortical electroencephalogram by thyrotropin-releasing hormone. *Exp. Neurol.* 69: 627-638.
5. Kalivas, P.W. and A. Horita. 1981. Neuroanatomical dissociation of thyrotropin-releasing hormone induced shaking behavior and thermogenic mechanisms. *Reg. Peptides* 1: 335-345.

6. Kalivas, P.W., S.M. Simasko and A. Horita. 1981. Effect of septohippocampal lesions on thyrotropin-releasing hormone antagonism of pentobarbital narcosis. *Brain Res.* 222: 253-266.
7. Santori, W.M., D.E. Schmidt, P.W. Kalivas and A. Horita. 1981. Failure of muscarinic blockade to antagonize analepsis induced by thyrotropin-releasing hormone and MK-77 in the rat. *Psychopharmacology* 74: 13-16.
8. Kalivas, P.W., C.B. Nemeroff and A.J. Prange, Jr. 1981. Increases in spontaneous motor activity following infusion of neurotensin into the ventral tegmental area. *Brain Res.* 229: 525-529.
9. Kalivas, P.W., C.B. Nemeroff and A.J. Prange, Jr. 1982. Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin. *Eur. J. Pharmacol.* 78: 471-474.
10. Kalivas, P.W. 1982. Histamine-induced arousal in the conscious and pentobarbital pretreated rat. *J. Pharmacol. Exp. Ther.* 222: 37-42.
11. Kalivas, P.W., B. Gau, C.B. Nemeroff and A.J. Prange, Jr. 1982. Antinociception after microinjection of neurotensin into the central amygdaloid nucleus of the rat. *Brain Res.* 243: 279-286.
12. Kalivas, P.W., L. Jennes, C.B. Nemeroff and A.J. Prange, Jr. 1982. Neurotensin: Topographical distribution of brain sites involved in hypothermia and antinociception. *J. Comp. Neurol.* 210: 225-238.
13. Jennes, L., W. Stumpf and P.W. Kalivas. 1982. Neurotensin: Topographical distribution in rat brain by immunohistochemistry. *J. Comp. Neurol.* 210: 213-224.
14. Kalivas, P.W., S.K. Burgess, C.B. Nemeroff and A.J. Prange, Jr. 1983. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. *Neuroscience* 8: 496-505.
15. Widerlov, E., P.W. Kalivas, M.H. Lewis, A.J. Prange, Jr. and G.R. Breese. 1983. Influence of cholecystokinin on central monoaminergic pathways. *Regul. Pept.* 6: 99-109.
16. Kalivas, P.W., E. Widerlov, D. Stanley, G. Breese and A.J. Prange, Jr. 1983. Enkephalin action on the mesolimbic system: A dopamine-dependent and a dopamine-independent increase in locomotor activity. *J. Pharmacol. Exp. Ther.* 227: 229-237.
17. Horita, A., P.W. Kalivas and S.M. Simasko. 1983. Thyrotropin releasing hormone (TRH): Possible physiological functions not related to the neuroendocrine system. *Rev. Pure Appl. Pharmacol. Sci.* 4: 111-125.
18. Kalivas, P.W. 1984. Neurotensin in the ventromedial mesencephalon of the rat: Anatomical and functional considerations. *J. Comp. Neurol.* 226: 495-507.
19. Kalivas, P.W., C.B. Nemeroff and A.J. Prange, Jr. 1984. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. *Neuroscience* 11: 919-930.
20. Schulz, D.W., P.W. Kalivas, C.B. Nemeroff and A.J. Prange, Jr. 1984. Bombesin-induced locomotor hyperactivity: Evaluation of the involvement of the mesolimbic dopamine system. *Brain Res.* 304: 377-382.

21. Kalivas, P.W. and J.S. Miller. 1984. Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens. *Brain Res.* 300: 157-160.
22. Nemeroff, C.B., P.W. Kalivas, R.N. Golden and A.J. Prange, Jr. 1984. Behavioral effects of hypothalamic hypophysiotropic hormones, neurotensin, substance P and other neuropeptides. *Pharmacol. Ther.* 24: 1-56.
23. Long, J.B., P.W. Kalivas, W.W. Youngblood, A.J. Prange, Jr. and J.S. Kizer. 1984. Possible involvement of serotonergic neurotransmission in neurotensin but not morphine analgesia. *Brain Res.* 310: 35-41.
24. Kalivas, P.W. and J.S. Miller. 1984. Substance P modulation of dopamine in the nucleus accumbens. *Neurosci. Lett.* 48: 55-59.
25. Kalivas, P.W., J.S. Miller and L. Jennes. 1985. A catecholaminergic projection from the ventral tegmental area to the diagonal band of Broca: Modulation by neurotensin. *Brain Res.* 326: 229-238.
26. Kalivas, P.W., C.B. Nemeroff, J.S. Miller and A.J. Prange, Jr. 1985. Microinjection of neurotensin into the ventral tegmental area produces hypothermia: Evaluation of dopaminergic mediation. *Brain Res.* 326: 219-227.
27. Kalivas, P.W. and J.S. Miller. 1985. Dopamine microinjection into the nucleus accumbens: Correlation between metabolism and behavior. *Biochem. Pharmacol.* 34: 284-286.
28. Kalivas, P.W., A. Deutch, J.E. Maggio, P.W. Mantyh and R.H. Roth. 1985. Substance K and substance P in the ventral tegmental area. *Neurosci. Lett.* 57: 241-246.
29. Kalivas, P.W. and M. Bronson. 1985. Mesolimbic dopamine lesions produce an augmented response to enkephalin. *Neuropharmacology* 24: 931-936.
30. Kalivas, P.W. and S. Taylor. 1985. Behavioral and neurochemical effect of daily injection with neurotensin into the ventral tegmental area. *Brain Res.* 358: 70-76.
31. Deutch, A.Y., J.E. Maggio, M.J. Bannon, P.W. Kalivas, S.-Y. Tam, M. Goldstein and R.H. Roth. 1985. Substance K and substance P differentially modulate mesolimbic and mesocortical systems. *Peptides* 6: 113-122.
32. Kalivas, P.W. 1985. Interactions between neuropeptides and dopamine neurons in the ventromedial mesencephalon. *Neurosci. Biobehav. Rev.* 9: 573-587.
33. Kalivas, P.W., S. Taylor and J.S. Miller. 1985. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat: I. Behavioral characterization. *J. Pharmacol. Exp. Ther.* 235: 537-543.
34. Kalivas, P.W. 1985. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat: II. Involvement of the mesolimbic dopamine system. *J. Pharmacol. Exp. Ther.* 235: 544-550.
35. Kalivas, P.W., R. Richardson-Carlson and G. Van Orden. 1986. Cross-sensitization between footshock stress and enkephalin-induced motor activity. *Biol. Psychiatry* 21: 939-950.

36. Kalivas, P.W. and R. Richardson-Carlson. 1986. Endogenous enkephalin modulation of dopamine neurons in the ventral tegmental area. *Am. J. Physiol.* 251: R243-R249.
37. Kalivas, P.W., R. Richardson-Carlson and P. Duffy. 1986. Neuromedin N mimics the actions of neurotensin in the ventral tegmental area but not in the nucleus accumbens. *J. Pharmacol. Exp. Ther.* 238: 1126-1131.
38. Ritter, R.C. and P.W. Kalivas. 1986. Cholecystokinin-induced suppression of locomotion is attenuated in capsaicin pretreated rats. *Peptides* 7: 587-590.
39. Kalivas, P.W., D. Stanley and A.J. Prange, Jr. 1987. Interaction between thyrotropin-releasing hormone and the mesolimbic dopamine system. *Neuropharmacology* 26: 33-38.
40. Latimer, L.G., P. Duffy and P.W. Kalivas. 1987. Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area. *J. Pharmacol. Exp. Ther.* 241: 328-337.
41. Kalivas, P.W. and P. Duffy. 1987. Sensitization to repeated morphine injection in the rat: Possible involvement of A10 dopamine neurons. *J. Pharmacol. Exp. Ther.* 241: 204-212.
42. Kalivas, P.W. and R. Abhold. 1987. Enkephalin release into the ventral tegmental area in response to stress: Modulation of mesocortical dopamine. *Brain Res.* 414: 339-348.
43. Vezina, P., P.W. Kalivas and J. Stewart. 1987. Sensitization occurs to the locomotor effects of morphine and the specific mu opioid receptor agonist, DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens. *Brain Res.* 417: 51-58.
44. Kalivas, P.W., L.G. Latimer and P. Duffy. 1987. Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat. *J. Pharmacol. Exp. Ther.* 242: 757-763.
45. DuMars, L.A., L.D. Rodger and P.W. Kalivas. 1988. Behavioral cross-sensitization between cocaine and enkephalin in the A10 dopamine region. *Behav. Brain Res.* 27: 87-91.
46. Austin, M.C. and P.W. Kalivas. 1988. The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior. *Brain Res.* 441: 209-214.
47. Hoffman, N.W., A.A. Gerall and P.W. Kalivas. 1988. Sexual refractoriness and locomotion effects on brain monoamines in male rat. *Physiol. Behav.* 41: 563-569.
48. Kalivas, P.W. and P. Duffy. 1988. Effects of daily cocaine and morphine treatment on somatodendritic and terminal field dopamine release. *J. Neurochem.* 50: 1498-1504.
49. Kalivas, P.W., L.A. DuMars and C. Skinner. 1988. Behavioral and neurochemical effects of acute and daily cocaine administration in rats. *J. Pharmacol. Exp. Ther.* 245: 485-492.
50. Kalivas, P.W. and B. Weber. 1988. Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine, and cocaine. *J. Pharmacol. Exp. Ther.* 245: 1095-1102.

51. Kalivas, P.W. and P. Duffy. 1989. Similar effects of daily cocaine and stress on mesocorticolimbic dopamine neurotransmission in the rat. *Biol. Psychiat.* 25: 913-928.
52. Dilts, R. and P.W. Kalivas. 1989. Autoradiographic localization of mu opioid and neurotensin receptors within the mesolimbic dopamine system. *Brain Res.* 488: 311-328.
53. Kalivas, P.W., A. Bourdelais, R. Abhold and L. Abbott. 1989. Somatodendritic release of endogenous dopamine: In vivo dialysis in the A10 dopamine region. *Neurosci. Lett.* 100: 215-219.
54. Austin, M.C. and P.W. Kalivas. 1989. Blockade of enkephalinergic and GABAergic mediated locomotion in the nucleus accumbens by muscimol in the ventral pallidum. *Jpn. J. Pharmacol.* 50: 487-490.
55. Kalivas, P.W., P. Duffy and J. Barrow. 1989. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. *J. Pharmacol. Exp. Ther.* 251: 378-387.
56. Samathanam, G., P. Duffy, P.W. Kalivas and S.R. White. 1989. A comparison of 5-hydroxytryptophan effects on rat lumbar spinal cord serotonin release and monosynaptic response amplitude. *Brain Res.* 501: 179-182.
57. Adams, J.D., P.W. Kalivas and C.A. Miller. 1989. The acute histopathology of MPTP in the mouse CNS. Ultrastructural and behavioral analysis. *Brain Res. Bull.* 23: 1-17.
58. Adachi, D.K., P.W. Kalivas and J.O. Schenk. 1990. Neurotensin binding to dopamine. *J. Neurochem.* 54: 1321-1328.
59. Austin, M.C. and P.W. Kalivas. 1990. Enkephalinergic and GABAergic modulation of motor activity in the ventral pallidum. *J. Pharmacol. Exp. Ther.* 252: 1370-1377.
60. Churchill, L., R.P. Dilts and P.W. Kalivas. 1990. Changes in gamma-aminobutyric acid, mu-opioid and neurotensin receptors in the accumbens-pallidal projection after discrete quinolinic acid lesions in the nucleus accumbens. *Brain Res.* 511: 41-54.
61. Kalivas, P.W. and P. Duffy. 1990. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. *Synapse* 5: 48-58.
62. Kalivas, P.W. 1990. Peptide modulation of dopamine neurons: Implications for schizophrenia. *Current Opinion in Psychiatry* 3: 113-116.
63. Bourdelais, A. and P.W. Kalivas. 1990. Amphetamine lowers extracellular GABA concentration in the ventral pallidum. *Brain Res.* 516: 132-136.
64. Dilts, R.P. and P.W. Kalivas. 1990. Autoradiographic localization of delta opioid receptors within the mesocorticolimbic dopamine system using radioiodinated [2-D-penicillamine, 5-D-penicillamine] enkephalin (¹²⁵I-DPDPE). *Synapse* 6: 121-132.
65. Finnell, R.H., S. Toloyan, M. van Waes and P.W. Kalivas. 1990. Preliminary evidence for cocaine-induced embryopathy in mice. *Toxicol. Appl. Pharmacol.* 103: 228-237.
66. Kalivas, P.W. and T. Duffy. 1990. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. *J. Neurosci.* 10: 2940-2949.

67. Kalivas, P.W., P. Duffy and H. Eberhardt. 1990. Modulation of A10 dopamine neurons by GABA agonists. *J. Pharmacol. Exp. Ther.* 253: 858-866.
68. Rowe, B.P., P.W. Kalivas and R.C. Speth. 1990. Autoradiographic localization of angiotensin II receptor binding sites on noradrenergic neurons of the locus coeruleus of the rat. *J. Neurochem.* 55: 533-540.
69. Steketee, J. and P.W. Kalivas. 1990. Effect of microinjections of apamin into the A10 dopamine region of rats: a behavioral and neurochemical analysis. *J. Pharmacol. Exp. Ther.* 254: 711-719.
70. Austin, M.C. and P.W. Kalivas. 1991. Dopaminergic involvement in locomotion elicited from the ventral pallidum/substantia innominata. *Brain Res.* 542: 123-131.
71. Heimer, L., D.S. Zahm, L. Churchill, P.W. Kalivas and C. Wohlton. 1991. Specificity in the projection patterns of accumbal core and shell in the rat. *Neuroscience* 41: 89-125.
72. Kalivas, P.W. and P. Duffy. 1991. A comparison of axonal and somatodendritic dopamine release using in vivo dialysis. *J. Neurochem.* 56: 961-967.
73. Churchill, L., A. Bourdelais, M.C. Austin, J.N. Crawley and P.W. Kalivas. 1991. GABA_A receptors containing alpha1 and beta2 subunits are mainly localized on neurons in the ventral pallidum. *Synapse* 8: 75-85.
74. Steketee, J.D., T.F. Murray and P.W. Kalivas. 1991. Possible role for G proteins in behavioral sensitization. *Brain Res.* 545: 287-291.
75. Sorg, B. and P.W. Kalivas. 1991. Effects of cocaine and footshock stress on extracellular dopamine levels in the ventral striatum. *Brain Res.* 559: 29-36.
76. Churchill, L., R. Dilts, and P.W. Kalivas. 1991. Autoradiographic localization of gamma-aminobutyric acid_A receptors within the ventral tegmental area. *Neurochem. Res.* 17: 101-106.
77. Samathanam, G.K., S.R. White, P.W. Kalivas, and P. Duffy. 1991. Effects of 5-hydroxytryptophan on extracellular serotonin in the spinal cord of rats with experimental allergic encephalomyelitis. *Brain Res.* 559: 37-43.
78. Samson, H.H., G.A. Tolliver, M. Haraguchi and P.W. Kalivas. 1991. Effects of d-amphetamine injected into the nucleus accumbens on ethanol reinforced behavior. *Brain Res. Bull.* 27: 267-271.
79. See, R.E., B. Sorg, M.T. Chapman, and P.W. Kalivas. 1991. In vivo assessment of dopamine release and metabolism in the ventral striatum following administration of dopamine D₁ and D₂ receptor agonists and antagonists. *Neuropharmacology* 30: 1269-1274.
80. Kalivas, P.W. and J. Stewart. 1991. Dopamine transmission in drug- and stress-induced behavioral sensitization. *Brain Res. Rev.* 16: 223-244.
81. Steketee, J.D. and P.W. Kalivas. 1991. Sensitization to psychostimulants and stress following injection of pertussis toxin into the A10 dopamine region. *J. Pharmacol. Exp. Ther.* 259: 916-924.

82. Bourdelais, A. and P.W. Kalivas. 1991. High sensitivity HPLC assay for GABA in brain dialysis studies. *J. Neurosci. Meth.* 39: 115-121.
83. Steketee, J.D., D.C. Striplin, T.F. Murray and P.W. Kalivas. 1992. Pertussis toxin in the A10 region increases dopamine synthesis and metabolism. *J. Neurochem.* 58: 811-816.
84. Steketee, J.D., B.A. Sorg and P.W. Kalivas. 1992. The role of the nucleus accumbens in sensitization to drugs of abuse. *Prog. Neuro-Psychopharmacol. Biol. Psychiat.* 16: 237-246.
85. Churchill, L. and P.W. Kalivas. 1992. Dopamine depletion produces augmented behavioral response to a mu, but not a delta opioid receptor agonist in the nucleus accumbens: Lack of a role for receptor upregulation. *Synapse* 11: 47-57.
86. Steketee, J.D. and P.W. Kalivas. 1992. Microinjection of the D₂ agonist, quinpirole, into the A10 dopamine region blocks amphetamine, but not cocaine-stimulated motor activity. *J. Pharmacol. Exp. Ther.* 261(2): 811-818.
87. Churchill, L., M.C. Austin and P.W. Kalivas. 1992. Dopamine and endogenous opioid regulation of picrotoxin-induced locomotion in the ventral pallidum after dopamine depletion in the nucleus accumbens. *Psychopharmacology* 108: 141-146.
88. Bourdelais, A.J. and P.W. Kalivas. 1992. Modulation of extracellular g-aminobutyric acid in the ventral pallidum using in vivo microdialysis. *J. Neurochem.* 58(6): 2311-2320.
89. Bourdelais, A.J. and P.W. Kalivas. 1992. Apomorphine decreases extracellular GABA in the ventral pallidum of rats with 6-OHDA lesions in the nucleus accumbens. *Brain Res.* 577: 306-311.
90. Klitenick, M.A., A.Y. Deutch, L. Churchill and P.W. Kalivas. 1992. Topography and function role of dopaminergic projections from the ventral mesencephalic tegmentum to the ventral pallidum. *Neuroscience* 50(2): 371-386.
91. Striplin, C.D. and P.W. Kalivas. 1992. Correlation between behavioral sensitization to cocaine and G protein ADP-ribosylation in the ventral tegmental area. *Brain Res.* 579: 181-186.
92. Churchill, L., R.S. Cross, T.L. Pazdernik, S.R. Nelson, D.S. Zahm, L. Heimer and P.W. Kalivas. 1992. Patterns of glucose use after bicuculline-induced convulsions in relationship to g-aminobutyric acid and μ -opioid receptors in the ventral pallidum—functional markers for the ventral pallidum. *Brain Res.* 581: 39-45.
93. Klitenick, M.A., P. DeWitte and P.W. Kalivas. 1992. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA. *J. Neuroscience* 12(7): 2623-2632.
94. Daugé, V., P.W. Kalivas, P. Duffy and B.P. Roques. 1992. Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine. *Brain Res.* 599: 209-214.
95. Churchill, L., R.P. Dilts and P.W. Kalivas. 1992. Autoradiographic localization of g-aminobutyric acid_A receptors within the ventral tegmental area. *Neurochem. Res.* 17(1): 101-106.

96. Sorg, B.A., S.-Y. Chen and P.W. Kalivas. 1993. Time course of tyrosine hydroxylase expression following behavioral sensitization to cocaine. *J. Pharmacol. Exp. Ther.* 266: 424-430.
97. Sorg, B. and P.W. Kalivas. 1993. Effects of cocaine and footshock stress on extracellular dopamine levels in the medial prefrontal cortex. *Neuroscience*. 53(3): 695-703.
98. Kalivas, P.W. and P. Duffy. 1993. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. *J. Neurosci.* 13(1): 266-275.
99. Kalivas, P.W. and P. Duffy. 1993. Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. *J. Neurosci.* 13(1): 276-284.
100. Sorg, B.A. and P.W. Kalivas. 1993. Behavioral sensitization to stress and psychostimulants. *Seminars in Neuroscience*, 5: 343-350.
101. Kalivas, P.W. 1993. Neurotransmitter regulation of dopamine neurons in ventral tegmental area. *Brain Res. Rev.* 18: 75-113.
102. Kalivas, P.W., M.S. Hooks and B.A. Sorg. 1993. The pharmacology and neural circuitry of sensitization to psychostimulants. *Behav. Pharmacol.* 4: 315-334.
103. Striplin, C. and P.W. Kalivas. 1993. Robustness of G protein changes in cocaine sensitization shown with immunoblotting. *Synapse* 14:10-15.
104. See, R.W., C. Striplin and P.W. Kalivas. 1993. Chronic haloperidol does not alter G protein α -subunit levels in rats. *Mol. Brain Res.* 19:219-221.
105. Kalivas, P.W., L. Churchill and M.A. Klitenick. 1993. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to VTA. *Neuroscience* 57:1047-1060.
106. Kalivas, P.W. and J.E. Alesdatter. 1993. Involvement of NMDA receptor stimulation in the VTA and amygdala in behavioral sensitization to cocaine. *J. Pharmacol. Exp. Ther.* 267: 486-495.
107. Alesdatter, J.E. and P.W. Kalivas. 1993. Inhibition of μ -opioid induced motor activity in the ventral pallidum by D₁ receptor blockade. *Behav. Pharmacol.* 4: 645-651.
108. Kalivas, P.W. 1994. Effect of protein kinase inhibitors on the actions of neurotensin in the ventral tegmental area. *Psychopharmacol.* 114: 175-180.
109. Hooks, M.S., D.N.C. Jones, S.G. Holtzman, J.L. Juncos, P.W. Kalivas and J.B. Justice, Jr. 1994. Individual differences in behavior following amphetamine GBR-12909 or apomorphine but not SKF-38393 or quinpirole. *Psychopharmacology.* 116: 217-225.
110. Hooks, M.S., P. Duffy, C. Striplin and P.W. Kalivas. 1994. Behavioral and neurochemical sensitization following cocaine self-administration. *Psychopharmacology.* 115: 265-272.
111. Klitenick, M.A. and P.W. Kalivas. 1994. Behavioral and neurochemical studies of opioid effects in the pedunculopontine nucleus and mediodorsal thalamus. *J. Pharmacol. Exp. Ther.* 269: 437-448.

112. White, S.R., P. Duffy and P.W. Kalivas. 1994. Effects of MDMA on neuronal excitability and extracellular levels of dopamine and serotonin in nucleus accumbens *in vivo*. *Neuroscience*. 62: 41-50.
113. Churchill, L. and P.W. Kalivas. 1994. A topographically-organized GABAergic projection from the ventral pallidum to the nucleus accumbens of the rat. *J. Comp. Neurol.* 345: 579-595.
114. Hooks, M.S., B.A. Sorg, and P.W. Kalivas. 1994. The relationship between mRNA levels and the locomotor response to novelty. *Brain Res.* 663: 312-316.
115. Hooks, M.S., J.L. Juncos, J. B. Justice, J.B. Jr., S.M, Meiergard, J.O. Schenk and P.W. Kalivas. 1994. Individual locomotor response to novelty predicts selective alterations in D₁ and D₂ receptors and mRNA. *J. Neurosci.* 14: 6144-6152.
116. Hooks, M.S. and P.W. Kalivas. 1994. Involvement of dopamine and excitatory amino acid transmission in novelty-induced motor activity. *J. Pharmacol. Exp. Ther.* 269: 976-988.
117. Kalivas, P.W. 1995. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. *Drug. Alcohol. Dep.* 37: 95-100.
118. Napier, T.C., I. Mitrovic, L. Churchill, M.A. Klitenick and P.W. Kalivas. 1995. Substance P projection from the nucleus accumbens to the ventral pallidum. Anatomy, electrophysiology and behavior. *Neuroscience* 69:59-70.
119. Kalivas, P.W. and Duffy, P. 1995. D₁ receptors modulate glutamate and GABA transmission in the ventral tegmental area. *J. Neurosci.* 15:5379-5389.
120. Hooks, M.S. and Kalivas, P.W. 1995. The role of mesoaccumbens - pallidal circuitry in novelty-induced behavioral activation. *Neuroscience* 64: 587-598.
121. Bell, K., Churchill, L., and Kalivas, P.W. 1995. GABAergic projection from ventral and globus pallidus to the subthalamic nucleus. *Synapse* 20: 10-18.
122. Churchill, L., Roques, B.P. and Kalivas, P.W. 1995. Dopamine depletion augments endogenous opioid-induced locomotion in the nucleus accumbens using both μ 1 and d2 opioid receptors. *Psychopharmacol.* 120: 347-355.
123. Pierce, R.C., Duffy, P. and Kalivas, P.W. 1995. Sensitization to cocaine and dopamine autoreceptor function in the nucleus accumbens. *Synapse* 20: 33-36.
124. Sorg, B.A., Guminski, B.J.M., Hooks, M.S. and Kalivas, P.W. 1995. Cocaine alters glutamic acid decarboxylase and preprotachykinin mRNA levels differentially in the nucleus accumbens core and shell. *Mol. Brain Res.* 29: 381-386.
125. Kalivas, P.W. and Duffy, P. 1995. Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. *Brain Res.* 675: 325-328.
126. Sorg, B.A., Hooks, M.S. and Kalivas, P.W. 1995. Neuroanatomy and neurochemical mechanisms of time-dependent sensitization. *Toxicol. Indust. Health.* 10: 369-386.
127. Harris, G.C. and Kalivas, P.W. 1996. α -adrenergic antagonism enhances the acute behavioral and neurochemical responses to cocaine and decreases cocaine self-administration. *Neuropsychopharmacol.* 14:194-204.

128. Churchill, L., Zahm, D.S., and Kalivas, P.W. 1996. The mediodorsal nucleus of the thalamus. I. Forebrain GABAergic innervation. *Neurosci.* 70: 93-102.
129. Churchill, L., Zahm, D.S., Duffy, T. and Kalivas, P.W. 1996. The mediodorsal nucleus of the thalamus. II. Behavioral and neurochemical effects of GABA agonists. *Neurosci.* 70: 103-112.
130. Pierce, R.C. and Kalivas, P.W. 1996. Amphetamine produces sensitized locomotion and dopamine release preferentially in the nucleus accumbens shell of rats administered repeated cocaine. *J. Pharmacol. Exp. Ther.* 275: 1019-1029.
131. Pierce, R.C., K. Bell, P. Duffy and P.W. Kalivas. 1996. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. *J Neurosci* 16: 1550-1560.
132. Johnson, K., Churchill, L., Klitenick, M.A., Hooks, M.S. and Kalivas, P.W. 1996. Involvement of the ventral tegmental area in locomotion elicited from the nucleus accumbens or ventral pallidum. *J.Pharmacol.Exp.Ther.*, 277: 1122-1131.
133. Bell, K. and Kalivas, P.W. 1996. Context-specific cross sensitization between systemic cocaine and intra-accumbens AMPA infusion in rats. *Psychopharmacol.*, 127: 377-383.
134. Pierce, R.C., B.Born, M.Adams, P.W.Kalivas. 1996. Repeated intra-VTA administration of SKF-38393 induces behavioral and neurochemical sensitization to a subsequent cocaine challenge. *J.Pharmacol.Exp.Ther.*, 278: 384-392.
135. Pierce, R.C., Duffy, P. and Kalivas, P.W. 1996. Changes in excitatory amino acid transmission in the nucleus accumbens associated with behavioral sensitization to cocaine during early withdrawal. *Neuroscience-Net*,
<http://www.neuroscience.com/abp09961/htm/index.html>
136. Prasad, B.M., Ulibarri, C., Kalivas, P.W. and Sorg, B.A. 1996. Effect of adrenalectomy on the initiation and expression of cocaine-induced sensitization. *Psychopharmacol*, 125: 265-273.
137. Lu, X-Y., Churchill, L. and Kalivas, P.W. 1997. Expression of D1 receptor mRNA in projections from the forebrain to the ventral tegmental area. *Synapse*, 25: 205-214.
138. Sorg, B.A., Davidson, D.L., Kalivas, P.W. and Prasad, B.M. 1997. Repeated daily cocaine alters subsequent cocaine-induced increase of extracellular dopamine in the medial prefrontal cortex. *J.Pharmacol.Exp.Ther.*, 281: 54-61.
139. Pierce, R.C. and P.W.Kalivas. 1997. Repeated cocaine treatment modifies the mechanisms by which amphetamine releases dopamine. *J.Neurosci.*, 17: 3254-3261.
140. Craft, R.M., Kalivas, P.W. and Stratmann, J.A. 1997. Sex differences in discriminative stimulus effects of morphine in the rat. *Behav.Pharmacol.* 7: 764-778.
141. Samson, H.H., Hodge, C.W., Erickson, H.L., Niehus, J.S., Gerhardt, G.A., Kalivas, P.W. and Floyd, E.A. 1997. The effects of local application of ethanol in the nucleus accumbens on dopamine overflow and clearance. *Alcohol*, 14: 485-492.

142. Kalivas, P.W., Pierce, R.C. and Sorg, B.A. 1997. A role for sensitization in craving and relapse in cocaine addiction. *J. Psychopharmacol.*, 12: 49-53.
143. Kalivas, P.W. and P. Duffy. 1997. Dopamine regulation of extracellular glutamate in the nucleus accumbens. *Brain Res*, 761: 173-177.
144. Lu, X-Y., Ghasemzadeh, B. and Kalivas, P.W. 1997. Expression of D1, D2, substance P and enkephalin mRNA in subpopulations of neurons in the nucleus accumbens. *Neuroscience*, 82: 767-780.
145. Pierce, R.C. and Kalivas, P.W. 1997. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. *Brain Res. Review*, 25: 192-216.
146. Pierce, R.C., Reeder, D.C., Hicks, J., Morgan, Z.R. and Kalivas, P.W. 1997. Bilateral ibotenic acid lesions of the dorsal prefrontal cortex disrupt the expression of behavioral sensitization to cocaine. *Neuroscience*, 82: 1103-1114.
147. Pierce, R.C. and Kalivas, P.W. 1997. The NMDA antagonist, dizocilpine (MK-801), attenuates cocaine self-administration without affecting mesoaccumbens dopamine transmission. *Psychopharmacol.*, 133: 188-195.
148. Cha, X-Y, Pierce, R.C., Kalivas, P.W., Mackler, S.A. 1997. NAC-1, a rat brain mRNA increased in the nucleus accumbens three weeks after chronic cocaine self-administration. *J. Neurosci.*, 17: 6864-6871.
149. Kalivas, P.W., Duffy, P. and White, S.R. 1998. MDMA elicits behavioral and neurochemical sensitization in rats. *Neuropsychopharmacol.*, 18: 469-479.
150. Kalivas, P.W. and Duffy, T. 1998. Repeated cocaine administration alters extracellular glutamate levels in the ventral tegmental area. *J. Neurochem.*, 70: 1497-1502.
151. Churchill, L., M.A. Klitenick and P.W. Kalivas. 1998. Dopamine depletion reorganizes projections from the nucleus accumbens and ventral pallidum that mediate opioid-induced motor activity. *J. Neurosci.*, 18: 8074-8085.
152. Kalivas, P.W., J. Cornish and M.B. Ghasemzadeh. 1998. Cocaine Craving and Paranoia: a combination of pharmacology and learning. *Psychiat. Annals*, 28: 569-576.
153. Pierce, R.C., E.A. Quick, D.C. Reeder, Z.R. Morgan, P.W. Kalivas. 1998. Calcium mediated second messengers modulate the expression of behavioral sensitization to cocaine. *J. Pharmacol. Exp. Ther.*, 286:1171-1176.
154. White, F.J. and P.W. Kalivas. 1998. Neuroadaptations involved in amphetamine and cocaine addiction. *Drug Alc. Depen.*, 51: 141-154.
155. Churchill, L., Bell, K., Urbina, M. and Kalivas, P.W. 1999. Repeated cocaine alters glutamate receptor subunits in the nucleus accumbens and ventral tegmental area of rats that develop behavioral sensitization. *J. Neurochem*, 72: 2397-2403.
156. Lu, X-Y, Ghazemsadeh, B. and Kalivas, P.W. 1999. Regional distribution and cellular localiation of GABAB1 receptor mRNA in rat brain. *J. Comp. Neurol.*, 407: 166-182.
157. Kalivas, P.W., P. Duffy, X-Y. Cha and S.A. Mackler. 1999. Interrupted expression of NAC-1 augments the behavioural responses to cocaine. *Synapse*, 33: 153-159.

158. Ghasemzadeh, M.B., L.C. Nelson, X-Y. Lu and P.W. Kalivas. 1999. Neuroadaptations in ionotropic and metabotropic glutamate receptors by chronic cocaine. *J.Neurochem.*, 72: 157-165.
159. Lu, X-Y., M.B. Ghasemzadeh and P.W. Kalivas. 1999. Expression of glutamate receptor subunits/subtype in nucleus accumbens projection neurons. *Mol.Brain Res.*, 63: 287-296.
160. Romanides, A.J., P. Duffy and P.W. Kalivas. 1999. Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. *Neuroscience*, 92: 97-106.
161. Cornish, J., P. Duffy and P.W. Kalivas. 1999. A role for glutamate transmission in the relapse to cocaine-seeking behavior. *Neuroscience*, 93: 1359-1367.
162. Hu, G., P. Duffy, C. Swanson, B. Ghasemzadeh and P.W. Kalivas. 1999. The regulation of dopamine transmission by metabotropic glutamate receptors. *J.Pharmacol.Exp.Ther.*, 289: 412-416.
163. Kalivas, P.W. and M. Nakamura. 1999. Neuronal systems for behavioral activation and reward. *Curr Op Neurobiol*, 9: 223-227.
164. Nakamura, M., K. Bell, J. Cornish and P.W. Kalivas. 1999. Neural substrates mediating context-dependent sensitization. *Psychobiol.*, 27: 287-291.
165. Churchill, L. and P.W. Kalivas. 1999. Involvement of the mediodorsal thalamus and midbrain extrapyramidal area in opioid-induced locomotion elicited from the nucleus accumbens or ventral pallidum. *Behav. Brain Res.*, 104: 63-71.
166. Ghasemzadeh, M.B., R.C. Pierce and P.W. Kalivas. 1999. The monoamine neurons of the rat brain preferentially express a novel splice variant of a1 subunit of the N-type calcium channel. *J.Neurochem.*, 73: 1718-1723.
167. Swanson, C. and P.W. Kalivas. 2000. Regulation of motor activity by metabotropic glutamate receptors in the nucleus accumbens and ventral tegmental area. *J.Pharmacol.Exp.Ther.*, 292: 406-414.
168. Bell, K., P. Duffy and P.W. Kalivas. 2000. Context specific enhancement of glutamate transmission by cocaine. *Neuropsychopharmacol.*, 23: 335-344.
169. Vanderschuren, LJMJ and PW Kalivas. 2000. Alterations in dopaminergic and glutamatergic signaling in the induction and expression of behavioral sensitization. *Psychopharmacol.*, 151: 99-120.
170. Mackler, SA, L Korutla, XY Cha, MJ Koebe, KM Fournier, MS Bowers and PW Kalivas. 2000. NAC-1 is a brain POZ/BTB protein that can prevent behavioral sensitization in the rat. *J.Neuroscience*, 20: 6210-6217.
171. Cornish JL and PW Kalivas. 2000. Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. *J.Neuroscience*, 19: 1-5.
172. Kalivas, PW, D Jackson, A Romanidies, L Wyndham, P Duffy. 2001. Pallidal projections to the thalamus regulate working spatial memory. *Neuroscience*, 104: 129-136.

173. Cornish JL and PW Kalivas. 2001. Repeated cocaine administration into the rat ventral tegmental area produces behavioral sensitization to a systemic cocaine challenge. *Behav Brain Res*, 126: 205-209.
174. Cornish JL and PW Kalivas. 2001. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. *J Addictive Dis*, 20: 43-54.
175. Cornish, JL, M Nakamura and PW Kalivas 2001. Dopamine-independent locomotion following blockade of NMDA receptors in the ventral tegmental area. *J.Pharmacol.Exp.Ther.*, 298: 226-233.
176. Swanson, CJ, DA Baker, D Carson, PF Worley and PW Kalivas. 2001. Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: A potential role for Homer 1b/c. *J Neuroscience*. 21: 9043-9052.
177. McFarland, K. and PW Kalivas. 2001. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. *J Neuroscience*, 21: 8655-8663.
178. Xi ZX, H Shen, D Carson, DA Baker and PW Kalivas. 2002. Inhibition of glutamate release by group II metabotropic glutamate receptors. *J.Pharmacol ExpTher*, 300: 162-171
PMID:20371233.
179. Trantham, H, KK Szumlinski, K. McFarland, PW Kalivas and A Lavin. 2002. Repeated cocaine administration modulates electrophysiological properties of prefrontal cortical neurons. *Neuroscience*, 113: 749-753.
180. Baker, DA, Xi, Z-X, Shen, H, Swanson, CJ and PW Kalivas. 2002. The primary source and neuronal function of in vivo extracellular glutamate. *J.Neuroscience*, 22: 9134-9141.
181. Toda, S, JF McGinty and PW Kalivas. 2002. Long-lasting alterations in gene expression in mesocorticolimbic circuitry after chronic cocaine administration: a DNA microarray study. *J.Neurochem*, 82: 1290-1299.
182. Xi, Z-X, S Ramamoorthy, DA Baker, H Shen, DJ Samuvel and PW Kalivas. 2002. Modulation of group II glutamate receptor signaling by chronic cocaine. *J.Pharmacol ExpTher*, 308: 608-615.
183. Baker, DA, McFarland K, Lake RW, Shen H, Ghasemzadeh MB, Tang X, Toda S and PW Kalivas. 2003. Reduced extracellular glutamate and cystine-glutamate exchange underlie cocaine-seeking behavior *Nat Neuroscience*, 6: 743-749.
184. Szumlinski KK, KA Frys and PW Kalivas. 2003. Pretreatment with serotonin 5HT3 receptor antagonists does not prevent the development of long-term motor sensitization to cocaine. *Psychopharmacol*, 165:329-336.
185. Xi ZX, H Shen, D Carson, DA Baker and PW Kalivas. 2003. Group III metabotropic glutamate receptors regulate extracellular glutamate in the nucleus accumbens. *J Neurochem*, 87: 1204-12.
186. Xi, Z-X, S Ramamoorthy, H Shen, R Lake, DJ Samuvel and PW Kalivas. 2003. Neuroadaptations in GABA transmission in the nucleus accumbens following repeated cocaine. *J.Neuroscience*, 23: 3498-3505.

187. McFarland K, CC Lapish and PW Kalivas. 2003. Glutamate, not dopamine, in the accumbens core mediates cocaine-induced reinstatement of drug-seeking behavior. *J. Neuroscience*, 23: 3531-3537.
188. Kalivas PW and K McFarland. 2003. Brain circuitry and the reinstatement of drug-seeking behavior. *Psychopharmacology*, 168: 44-56.
189. Middaugh LD, Szumlinski KK, Van Patten Y, Marlow A-LB and PW Kalivas. 2003. Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone. *Alcoholism: Clin Exp Res*, 27: 1892-1900.
190. Pacharinsak C, Greene SA, Keegan RD and PW Kalivas. 2003. Postoperative analgesia in dogs receiving epidural morphine plus medetomidine. *J. Vet Pharmacol. Therap.* 26: 1-7.
191. Bowers MS and PW Kalivas. 2003. Forebrain astroglial plasticity is induced following withdrawal from repeated cocaine administration. *Eur J Neuroscience*, 17: 1273-8.
192. Ghasemzadeh, MB, LK Permenter, R Lake, PF Worley and PW Kalivas. 2003. Homer1 proteins and AMPA receptors regulate cocaine-induced behavioral plasticity. *Eur J Neuroscience*, 18: 1645-51.
193. Toda, S, LF Alguacil and PW Kalivas. 2003. Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptors in the rat nucleus accumbens. *J Neurochem*, 87: 1478-1484.
194. Szumlinski K, K Fryes and PW Kalivas. 2004. Dissociable roles for the dorsal and median raphe in the facilitatory effect of 5-HT1A receptor stimulation upon cocaine-induced locomotion and sensitization. *Neuropsychopharmacol.*, 29: 1675-1687.
195. McFarland K, SB Davidge, CC Lapish and PW Kalivas. 2004. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. *J Neuroscience*, 24: 1551-1560.
196. Bowers MS, K McFarland, RW Lake, YK Peterson, CC Lapish, ML Gregory, SM Lanier and PW Kalivas. 2004. Activator of G-protein signaling 3: A gatekeeper of cocaine sensitization and drug-seeking. *Neuron*, 42: 269-281.
197. Kalivas PW, KK Szumlinski and P Worley. 2004. Homer2 gene deletion in mice produces a phenotype similar to chronic cocaine treated rats. *Neurotox Res*, 6: 385-388.
198. Szumlinski, KK, MH Dehoff, S Kang, LD Middaugh, KA Frys, T Berry, PF Worley and PW Kalivas. 2004. Homer proteins regulate vulnerability to cocaine. *Neuron*, 43: 401-413.
199. Melendez RI, MT Bardo, ML Gregory and PW Kalivas. 2004. Impoverished rearing environment alters working memory and metabotropic glutamate receptor expression and function in the prefrontal cortex. *Neuropsychopharmacol*, 29:1980-1987.
200. Kalivas, PW. 2004. Glutamate systems and addiction. *Curr Op Pharmacol*, 4: 23-29.
201. Kalivas, PW. 2004. Recent understanding in the mechanisms of addiction. *Curr Psychiat Rep*, 6: 347-351.

202. Moran, M, K McFarland, RI Melendez, PW Kalivas and J Seamans. 2005. Cystine-glutamate exchange regulates synaptic transmission. *J Neuroscience*, 25: 6389-6393.
203. Melendez, RI, MP Hicks, SS Cagle and PW Kalivas. 2005. Ethanol exposure attenuates glutamate transporter function in the nucleus accumbens. *Alcohol Clin Exp Res*, 29: 326-332.
204. Kalivas, PW, N Volkow. 2005. The neural basis of addiction: A pathology of motivation and choice. *Am J Psychiatry*, 162: 1403-1413.
205. Szumlinski, K, KD Lominac, MJ Kleschen, EB Oleson, M Dehoff, M Schwartz, P Seeberg, PF Worley, PW Kalivas. 2005. Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. *Genes Br Behav*, 4: 273-288.
206. Tang, X-C, K McFarland, S Cagle and PW Kalivas. 2005. The reinstatement of cocaine-seeking requires endogenous stimulation of mu opioid receptors. *J Neuroscience*, 25: 4512-4520.
207. Melendez, R., J Vuthiganon and PW Kalivas. 2005. Regulation of extracellular glutamate in the prefrontal cortex: Focus on metabotropic glutamate receptors and cystine-glutamate exchange. *J Pharmacol Exp Ther*, 314: 139-147.
208. Volkow, ND, G-J Wang, J Ma, JS Fowler, C Wong, JM Swanson and PW Kalivas. 2005. Activation of orbitofrontal cortex by intravenous methylphenidate in cocaine addicts but not in controls: Relevance to drug craving. *J Neuroscience*, 25: 3932-3939.
209. Kalivas, PW, ND Volkow and J Seamans. 2005. Unmanageable motivation in addiction: A pathology in prefrontal-accumbens glutamate transmission. *Neuron*, 45: 647-650.
210. Korutla, L, Champtiaux, N, Kalivas, PW and SA Mackler. 2005. Activity dependent subcellular localization of NAC1. *Eur J Neuroscience*, 22: 397-403.
211. Szumlinski, K, K Lominac, E Oleson, J Walker, A Mason, M Dehoff, M Klugmann, S Cagles, K Welt, P Worley, L Middaugh and PW Kalivas. 2005. Homer2 is necessary for ethanol-induced neuroplasticity. *J Neuroscience*, 25: 7054-7061.
212. Lominac, KD, B Oleson, M Pava, MK Schwarz, PF Worley, M Klugmann, MJ During, PW Kalivas and KK Szumlinski. 2005. Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. *J Neuroscience*, 25: 11586-11594.
213. LaRowe, SD, P Mardikian, R Malcolm, H Myrick, PW Kalivas, K McFarland, M Saladin, A McRae, K Brady. 2005. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. *Am J Addict*, 15: 105-110.
214. Kalivas, PW. 2005. How do we determine which drug-induced neuroplastic changes are important? *Nat Neuroscience*, 8: 1440-1441.
215. Szumlinski, KK, KE Abernathy, EB Oleson, M Klugmann, KD Lominac, D-Y He, D Ron, M During and PW Kalivas. 2006. Homer isoforms differentially regulate cocaine-induced neuroplasticity. *Neuropsychopharmacol*, 31: 768-777.
216. Champtiaux, N, PW Kalivas, M Bardo. 2006. Contribution of α 2-containing nicotinic acetylcholine receptors in the ventral tegmental area to cocaine-induced behavioral sensitization in rats. *Behav Br Res*, 168: 120-126.

217. Toda, S., H-W Shen, S Cagle and PW Kalivas. 2006. Regulation of actin binding proteins contributes to cocaine-induced behavioral plasticity. *J Neuroscience*, 26: 1579-1587.
218. Peters, J and PW Kalivas. 2006. A role for nucleus accumbens group II metabotropic glutamate receptors in cocaine-induced reinstatement. *Psychopharmacol*, 186: 143-149.
219. Nogueira, L, PW Kalivas and A Lavin. 2006. Long-term neuroadaptations produced by withdrawal from repeated cocaine treatment: Role of dopaminergic receptors in modulating cortical excitability. *J Neuroscience*, 26: 12308-12313.
220. Shih AY, H Erb, X Sun, S Toda, PW Kalivas and TH Murphy. 2006. Cystine/glutamate exchange modulates glutathione supply for cell proliferation and neuroprotection from oxidative stress. *J Neuroscience*, 26:10514-10523.
221. Szumlinski, KK, PW Kalivas and PF Worley. 2006. Homer proteins: implications for neuropsychiatric disorders. *Curr Op Neurobiol*, 16: 251-257.
222. Kalivas PW and XT Hu. 2006. Exciting inhibition in psychostimulant addiction. *Tr Neurosci*, 29:610-616.
223. Melendez RI, LD Middaugh and PW Kalivas. 2006. Development of an alcohol deprivation and escalation effect in C57BL/6J mice. *Alcohol Clin Exp Res*, 30: 2017-2025.
224. Zhou W, J Liu, F Zhang, S Tang, H Zhu, M Lai and PW Kalivas. 2007. Possible role of acetylcholine transmission in nucleus accumbens and ventral tegmental area in heroin-seeking induced by conditioned cues. *Neuroscience*, 144: 1209-1218.
225. Pacchioni AM, J Vallone, RI Melendez, A Shih, TH Murphy and PW Kalivas. 2007. Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity. *Brain Res*, 1127: 26-35.
226. Mardikian, PN, SD LaRowe, S Hedden, PW Kalivas and RJ Malcolm. 2007. An open label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study. *Prog Neuro-Psychoph Biol Psychiat*, 31: 389-394.
227. LaRowe, SD, H Myrick, S Hedden, P Mardikian, M Saladin, A McRae, K Brady, PW Kalivas and R Malcolm. 2007. Is cocaine desire reduced by N-acetylcysteine? *Am J Psychiat*, 164: 1115-1117.
228. Knackstedt L and PW Kalivas. 2007. Extended access to cocaine self-administration enhances drug-primed reinstatement but not behavioral sensitization. *J Pharmacol Exp Ther*, 322: 1103-1109.
229. Shen H, L Korutla, N Champetieux, S Toda, R LaLumiere, J Vallone, M Klugmann, JA Blendy, SA Mackler and PW Kalivas. 2007. NAC1 translocates the proteasome complex into dendritic spines. *J Neuroscience*, 27: 8903-8913.
230. Kalivas PW. 2007. Neurobiology of cocaine addiction: Implications for new pharmacotherapy. *Am J Addict*, 16: 71-78, 2007.
231. Kalivas PW. 2007. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. *Dialogues Clin Neuro* 9: 167-175.

232. Torregrossa MM and PW Kalivas. 2008. Microdialysis and the neurochemistry of addiction. *Pharmacol Biochem Behav*, 90: 261-272. PMID 17928041.
233. Mackler S, A Pacchioni, R Dgnan, Y human, AC Conti, PW Kalivas and JA Blendy. 2008. Requirement for NAC1 in acute but not chronic psychomotor stimulant response. *Behav Br Res*, 197: 48-55.
234. Zhou W and PW Kalivas. 2008. N-acetylcysteine facilitates extinction and induces enduring reductions in cue- and heroin-induced drug-seeking. *Biol Psychiat*, 63: 338-340.
235. Kalivas PW and O'Brien C. 2008. Addiction as a disease of staged neuroplasticity. *Neuropsychopharm Rev*, 33:166-180.
236. Thomas MJ, PW Kalivas, Y Shaham. 2008. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. *Brit J Pharmacol*, 154: 327-342.
237. Torregrossa MM and PW Kalivas. 2008. Neurotensin in the ventral pallidum increases extracellular GABA and differentially affects cue- and cocaine-primed reinstatement. *J Pharmacol Exp Ther*, 325: 556-566.
238. Kalivas PW. 2008. Addiction as a pathology in prefrontal cortical regulation of corticostriatal habit circuitry. *Neurotox Res*, 14: 185-190. PMID: 19073425
239. Peters J, Vallone J, Laurendi K and PW Kalivas. 2008. Opposing roles for the ventral prefrontal cortex and basolateral amygdala on spontaneous recovery of cocaine-seeking. *Psychopharmacol*, 197: 319-326.
240. LaLumiere RT and PW Kalivas. 2008. Glutamate release in the nucleus accumbens core is necessary for heroin-seeking. *J Neuroscience*, 28:3170-3177.
241. LaLumiere RT and PW Kalivas. 2008. Cocaine addiction: mechanisms of action. *Psychiat Ann*, 38: 252-258.
242. Peters J, R LaLumiere and PW Kalivas. 2008. Activity in infralimbic cortex suppresses cocaine relapse. *J Neuroscience*, 28: 6046-6053. PMID: 18524910
243. Shen H, S Sesack, S Toda and PW Kalivas. 2008. Automated quantification of dendritic spine density and spine head diameter in medium spiny neurons. *Br Struct Func*, 213: 149-158. PMID: 18675832
244. Torregrossa MM, X-C Tang and PW Kalivas. 2008. The glutamatergic projection from the prefrontal cortex to the nucleus accumbens core is required for cocaine-induced decreases in ventral pallidal GABA. *Neurosci Lett*, 438: 142-145. PMID: 18455875
245. Nahas Z, Y Jiang, YH Zeidan, A Bielawska, Z Szulc, L DeVane, PW Kalivas and YA Hannun. 2009. Anti-ceramidase LCL385 acutely reduces BCL-2 expression in hippocampus but is not associated with an increase of learned helplessness in rats. *Behav Br Res*, 197: 41-44.
246. Pendyam S, A Mohan, PW Kalivas and S Nair. 2009. Computational model of extracellular glutamate predicts neuroadaptations by chronic cocaine. *Neuroscience*, 158: 1266-1276. PMID: 19103434

247. Pacchioni AM, BS Vallone, PF Worley and PW Kalivas. 2009. Neuronal pentraxins modulate cocaine-induced neuroadaptations. *J Pharmacol Exp Ther*, 328: 183-192. PMID: 18840757
248. Kalivas, PW, RT LaLumiere, L Knackstedt and H Shen. 2009. Glutamate transmission in addiction. *Neuropharmacology*, 56: 169-173. PMID: 18675832
249. Zhou W, F Zhang, H Liu, S Tang, M Lai, H Zhu and PW Kalivas. 2009. Effects of training and withdrawal periods on conditioned cue-induced heroin seeking in an animal model of relapse. *Psychopharmacol*, 203: 677-684. PMID: 19043694
250. Wiggins A, AM Pacchioni and PW Kalivas. 2009. Integrin expression is altered after acute and chronic cocaine. *Neurosci Lett*, 450: 321-323. PMID: 19073234
251. Moussawi K, AM Pacchioni, M Moran, MF Olive, JT Gass, A Lavin and PW Kalivas. 2009. N-acetylcysteine reverses cocaine induced metaplasticity. *Nat Neurosci*, 12: 182-189. PMID: 19136971, PMCID: PMC2661026
252. Shen HW, S Toda, K Moussai, A Bouknight, S Zahm and PW Kalivas. 2009. Altered dendritic spine plasticity in cocaine-withdrawn rats. *J Neuroscience*, 29: 2876-2884. PMID: 19261883, PMCID: PMC2698814.
253. Knackstedt AL, S LaRowe, P Mardikian, R Malcolm, H Upadhyaya, S Hedden, A Markou and PW Kalivas. 2009. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. *Biol Psychiat*, 65: 841-845. PMID: 1910343
254. Peters J, PW Kalivas and G Quirk. 2009. Shared prefrontal mechanisms regulating the extinction of both fear and addiction. *Learning Memory*, 16: 279-288. PMID: 19380710
255. Knackstedt L and PW Kalivas. 2009. Glutamate and reinstatement. *Curr Op Pharmacol*, 9: 59-64. PMID: 1957986
256. Saccone, SF, LJ Bierut, EJ Chesler, PW Kalivas, C Lerman, AW Bergen, NL Saccone, GR Uhl, C-Y Li, D Goldowitz, V Philip, HJ Edenberg, S Sherry, M Feolo, RK Moyzis and JL Rutter. 2009. Supplementing high-density SNP microarrays for additional coverage of disease-related genes: Addiction as a paradigm. *PLoS ONE*, 4: e5225. PMID: 19381300
257. Ghasemzadeh MB, Windham LK, Lake RW, Acker CJ and PW Kalivas. 2009. Cocaine activates Homer1 immediate early gene transcription in the mesocorticolimbic circuit: differential regulation by dopamine and glutamate signaling. *Synapse*, 63:42-53. PMID: 18932227
258. Kalivas, PW. 2009. The glutamate homeostasis hypothesis of addiction. *Nature Rev Neuroscience*, 10: 561-572. PMID: 19571793
259. Schwendt M, A Rocha, RE See, AM Pacchioni, JF McGinty and PW Kalivas. (2009) Extended self-administration of methamphetamine in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. *J Pharmacol Exp Ther*, 331: 555-562. PMID: 19648469
260. Berglind WJ, TW Whitfield, RT LaLumiere, PW Kalivas and JF McGinty. 2009. A single intra-PFC infusion of BDNF prevents cocaine-induced alterations in extracellular glutamate within the nucleus accumbens. *J Neuroscience*, 29: 3715-3719. PMID: 19321768

261. Pacchioni AM and PW Kalivas. 2009. The role of AMPAR trafficking mediated by neuronal pentraxins in cocaine-induced neuroadaptations. *Mol Cell Pharmacol*, 1: 183-192. PMID: 20336176
262. Knackstedt LA, RI Melendez and PW Kalivas. 2010. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine-seeking. *Biol Psychiat*, 67: 81-84. PMID: 19717140, PMCID: PMC2795043
263. Uys J, A Grey, A Wiggins, J Schwacke, K Schey and PW Kalivas. 2010. Matrix-assisted laser desorption/ionization tissue profiling of protein in the nucleus accumbens shell from cocaine sensitized rats. *J Mass Spectrometry*, 45: 97-103. PMID: 19918966, PMCID: PMC4153729
264. Moussawi K and PW Kalivas. 2010. Group II metabotropic glutamate receptors and drug addiction. *Eur J Pharmacol*, 639:115-122. PMID: 20371233, PMCID: PMC**
265. LaLumiere RT, KE Niehoff and PW Kalivas. 2010. The infralimbic cortex regulates the consolidation of extinction training after cocaine self-administration. *Learning & Memory*, 17: 168-175. PMID: 20332188, PMCID: PMC2852618
266. Rocha A and PW Kalivas. 2010. Role of the prefrontal cortex and nucleus accumbens in reinstating methamphetamine seeking. *Eur J Neurosci*, 31: 903-909. PMID: 20180839, PMCID: PMC**
267. Knackstedt, LA, R LaLumiere, K Moussawi, M Schwendt, M Klugmann and PW Kalivas. 2010. Extinction training after cocaine self-administration induces glutamatergic plasticity to inhibit cocaine seeking. *J Neuroscience*, 30: 7984-7992. PMID: 20534846, PMCID: PMC2893028
268. Reissner KJ and PW Kalivas. 2010. Using glutamate homeostasis as a target for treating addictive disorders. *Behav Pharmacol.*, 21: 514-522. PMID: 20634691, PMCID: PMC2932669
269. Toda S, HW Shen and PW Kalivas. 2010. Inhibition of actin cycling prevents cocaine-induced changes in spine morphology in the nucleus accumbens. *Neurotox Res*, 18: 410-15. PMID: 20336176, PMCID: PMC**
270. LaRowe, SD and PW Kalivas. 2010. The role of N-acetylcysteine to inhibit extinction responding in rats trained to self-administer cocaine. *Open Addict J*, www.bentham.org/open/toaddj/articles/V003/.../88TOADDJ.pdf
271. Kalivas PW, S Patel and JG Reves. 2010. Combining traditional neuroscience disciplines to promote academic growth: The creation of a department of neurosciences. *J So Car Med Assoc*, 106: 248-253. PMID: 21246173
272. Pendyam S, A Mohan, PW Kalivas and S Nair. 2011. Role of synaptic parameters in neurotransmitter homeostasis – a computational study. *Neural Computation*, 23: 984-1014. PMID: 21222526, PMCID: PMC**
273. Brown, TE, BR Lee, P Mu, D Ferguson, D Dietz, Y Lin, A Suska, M Ishikawa, YH Huang, H Shen, PW Kalivas, BA Sorg, M Bennet, RS Zukin, E Nestler, Y Dong and OM Schluter. 2011. Molecular and behavioral correlates of cocaine-induced generation of silent synapses in the nucleus accumbens. *J Neuroscience*, 31: 8163-8174, PMCID: PMC3286116.

274. Shen H, K Moussawi, W Zhou, S Toda and PW Kalivas. 2011. Heroin relapse requires LTP-like neuroplasticity mediated by NR2B-containing NMDA receptors. *PNAS*, 108: 19407-19412. PMID: 22084102, PMCID: PMC3228456.
275. Moussawi K, W Zhou, HW Shen, C Reichel, R See, DB Carr and PW Kalivas. 2011. Reversing cocaine-induced synaptic potentiation provides long-lasting protection from relapse. *PNAS*, 108: 385-390. PMID: 21173236, PMCID: PMC3017187.
276. Steketee JD and PW Kalivas. 2011. Drug Wanting: Behavioral sensitization and relapse to drug-seeking behavior. *Pharmacol Ther*, 63: 348-365. PMID 21490129; PMCID:PMC3082449.
277. Reissner KJ, JD Uys, JH Schwacke, C Walters, TE Dunn, JB Blumer, DM Townsend and PW Kalivas. 2011. Proteomic analysis reveals a role for AKAP signaling in the reinstatement of cocaine seeking. *JNeuroscience*, 31: 5648-58. PMID: 21490206, PMCID:PMC3595532.
278. Uys JD, P Hurt, TE Garrett, Y Manevich, S Hutchens, DM Townsend and PW Kalivas. 2011. Enduring changes in glutathione regulation following chronic cocaine. *Neuropsychopharmacol*, 36: 2551-2560. PMID: 21796101; PMCID: PMC3194081
279. Cramer SC, M Sur, C O'Brien, BH Dobkin, TD Sanger, J Trojanowski, JM Rumsey, R Hicks, J Cameron, D Chen, W Chen, L Cohen, C deCharms, CJ Duffy, GF Eden, E Eskandar, EE Fetz, R Filart, M Freund, S Haber, PW Kalivas, B Kolb, AF Kramer, M Lynch, J Matochik, HS Mayberg, PM McQuillen, MM Merzenich, R Nitkin, A Pascual-Leone, P Reuter-Lorenz, N Schiff, A Sharma, L Shekim, M Stryker, EV Sullivan, and S Vinogradov. 2011. Harnessing neuroplasticity for clinical applications. *Brain*, 134: 1591-1609. PMID: 21482550.
280. Reichel CM, K Moussawi, PH Do, PW Kalivas and RE See. 2011. Chronic N-acetylcysteine during abstinence or extinction following cocaine self-administration produces enduring reductions in drug-seeking. *J Pharmacol Exp Ther*, 337: 487-493 PMID: 21303920, PMCID: PMC3083102.
281. Kalivas PW and ND Volkow. 2011. New medications for drug addiction hiding in glutamatergic neuroplasticity. *Mol Psychiat*, 16: 974-986. PMID 21519339; PMCID: PMC21519339.
282. Wiggins A, RJ Smith, HW Shen and PW Kalivas. 2011. Integrins modulate relapse to cocaine-seeking. *J Neuroscience*, 31: 16177-16184. PMID: 22027492, PMCID: PMC3280336.
283. Javitt DC, D Schoepp, PW Kalivas, ND Volkow, C Zarate, K Merchant, M Bear, D Umbricht, M Hajos, W Potter and C-M Lee. 2011. Translating glutamate: from pathophysiology to treatment. *Sci Trans Med*, 2011 Sept 28; 3 (102)/ PMID: 21957170.
284. Reissner KJ, GC Sartor, EM Vazey, G Aston-Jones and PW Kalivas. 2011. Use of vivo-morpholinos for control of gene expression in the adult rat brain. *J Neurosci Meth*, 203: 354-360. PMID: 22027492, PMCID: PMC3857614
285. Moussawi, K, A Riegel, S Nair and PW Kalivas. 2011. Extracellular glutamate: Functional compartments operate in different concentration ranges. *Front Sys Neuroscience*, 5: 1-9, article 94. PMID: 22275885; PMCID: PMC3254064

286. Melendez R, J McGinty, PW Kalivas and HC Becker. 2012. Brain region-specific gene expression after chronic intermittent ethanol exposure and early withdrawal in C57BL/6J mice. *Addict Biol*, 17: 351-64. PMID 21812870; PMCID: PMC4153606
287. Olive FM, RM Cleva, PW Kalivas and RJ Malcolm. 2012. Glutamatergic medications for the treatment of drug and behavioral addictions. *Pharmacol Biochem Behav*, 100:801-810. PMID: 21536062; PMCID: PMC3154511
288. Kupchik, YM, K Moussawi, XC Tan, X Wang, BC Kalivas, R Kolokithas, KB Ogburn and PW Kalivas. 2012. The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine. *Biol Psychiat*, 71: 978-986. PMCID: PMC3340445
289. LaLumiere RT, KC Smith and PW Kalivas. 2012. Neural circuit competition for control of cocaine seeking: Role of the infralimbic cortex and nucleus accumbens shell. *Eur J Neuroscience*, 35: 614-22. PMCID: PMC3281521
290. Scofield M, L Korutla, PW Kalivas and SA Mackler. 2012. NAC1, a POZ/BTB protein binds to TDP-43, a potential role in amyotrophic lateral sclerosis. *Neuroscience*, 227: 44-54. PMCID: PMC3505276
291. Esparza, MA, F Bollanti, C Keller, MB Virgolini, M Lopez, A Brusco, PW Kalivas and LM Cancela. 2012. Stress-induced sensitization to cocaine: Actin cytoskeleton remodeling within mesocorticolimbic nuclei. *Eur J Neurosci*, 36: 3103-11. **
292. Trantham-Davidson, H, R LaLumiere, K Reissner, PW Kalivas and LA Knackstedt. 2012. Ceftriaxone normalizes synaptic transmission, glutamate transport and export following cocaine self-administration and extinction training. *J Neuroscience*, 32:12406-12410. PMCID: PMC3465971
293. Pendyam, S, A Mohan, PW Kalivas and S Nair. 2012. Role of perisynaptic parameters in neurotransmitter homeostasis – computational study of a general synapse. *Synapse*, 66: 608-621. PMID 22460547, **
294. LaRowe SD, PW Kalivas, JS Nicholas, PK Randall, PN Mardikian and RJ Malcolm. 2013. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. *Am J Addict*, 22: 443-52. PMID 23952889, **
295. Kupchik, Y and PW Kalivas. 2013. The rostral-medial ventral pallidum is a transition zone between the ventral pallidum and adjacent brain areas. *Br Struct Func*, 218: 1487-1500. PMID 23143342; PMCID: PMC3600056
296. Garcia-Keller C, SA Marinez, A Esparza, F Bollati, PW Kalivas and LM Cancela. 2013. Cross-sensitization between cocaine and acute restraint stress is associated with sensitized dopamine but not glutamate release in the nucleus accumbens. *Eur J Neuroscience*, 37: 982-985. PMID 23360446; **
297. Lewerenz J, S Hewett, Y Huang, M Lambros, PW Gout, PW Kalivas, A Massie, I Smolders, A Methner, M Pergande, SB Smith, V Ganapathy and P Maher. 2013. The cystine/glutamate antiporter system xc- in health and disease: From molecular mechanisms to novel therapeutic opportunities. *Antiox Redox Signaling*, 18: 522-555. PMID 22667998; PMCID: PMC3545354

298. Wang XS, K Moussawi, HW Shen and PW Kalivas. 2013. Role of mGluR5 neurotransmission in reinstated cocaine-seeking. *Addict Biol*, 18: 40-49. PMID 22340009, PMCID: PMC3360124
299. Stefanik MT, K Moussawi, YM Kupchik, KC Smith, RL Miller, ML Huff, K Deisseroth, PW Kalivas and RT LaLumiere. 2013. Optogenetic inhibition of cocaine seeking in rats. *Addict Biol*, 18: 50-53. PMID 22823160; PCMID: PMC3578202
300. Post RM and PW Kalivas. 2013. Bipolar disorder and substance abuse: Comorbidity and cross-sensitization. *Brit J Psychiat*, 202: 172-176. PMID 23455710, **
301. Shen H and PW Kalivas. 2013. Reduced LTP and LTD in prefrontal cortex synapses in the nucleus accumbens after heroin self-administration. *Int J Neuropsychopharmacol*, 16: 1165-1167. PMID 23110855, **
302. Gipson CD, YM Kupchik, H Shen, KJ Reissner, CA Thomas and PW Kalivas. 2013. Relapse induced by cues predicting cocaine depends on rapid, transient synaptic potentiation. *Neuron*, 77: 867-872. PMID 23473317, PMCID: PMC3619421
303. Gipson CD, KJ Reissner, YM Kupchik, AW Smith, NM Stankeviciute, ME Hensley-Simon and PW Kalivas. 2013. Nicotine relapse is mediated by glutamatergic plasticity. *PNAS*, 110: 9124-9129. PMID 23671067, PMCID: PMC3670307
304. Smith, RJ, MK Lobo, S Spencer and PW Kalivas. 2013. Cocaine-induced adaptations in D1- or D2-expressing accumbens projection neurons: Not synonymous with classical direct and indirect pathways. *Curr Op Neurobiol*, 23: 456-52. PMID 23428656, PMCID: PMC3681928
305. Reissner KJ, CA Thomas, RM Brown, S Spencer and PW Kalivas. 2013. The glial modulator propentofylline impairs reinstatement in a rat model of cocaine relapse. *Neuropsychopharmacology*, 39: 499-506. PMID 23985782, PMCID: PMC3870775
306. Stefanik MT, YM Kupchik, RM Brown and PW Kalivas. 2013. Optogenetic evidence that pallidal, not nigral projections from the nucleus accumbens core are necessary for reinstating cocaine seeking. *J Neuroscience*, 33: 13654-62. PMID 23966687; PMCID: PMC3755713
307. Stefanik MT and PW Kalivas. 2013. Optogenetic dissection of basolateral amygdala projections during cue-induced reinstatement of cocaine seeking. *Frontiers Behavioral Neuroscience*, 7: 213 PMID 24399945; PMCID: PMC3871970
308. Stankeviciute NM, MD Scofield, PW Kalivas and CD Gipson. 2014. Rapid, transient potentiation of dendritic spines in context-induced relapse to cocaine seeking. *Addict Biol*, 10: 972-974. PMID 23648005, PMCID: PMC3742620
309. Spencer S, GC Wuintero, RM Brown, CA Thomas, KJ Reissner and PW Kalivas. 2014. Alpha2delta-1 required for cocaine-induced drug seeking. *J Neuroscience*, 25: 8605-11. PMCID: PMC4061396
310. Scofield MD and PW Kalivas. 2014. Astrocytic dysfunction and addiction: Consequences of impaired glutamate homeostasis. *The Neuroscientist*, 20: 610-22. PMCID: PMC4913887

311. Shen, H, MD Scofield, H Boger, M Hensley and PW Kalivas. 2014. Synaptic glutamate spillover mediates heroin relapse. *J Neuroscience*, 34: 5649-5657. PMC3988415
312. Mahler, SV, M Hensley-Simon, RT LaLumiere, P Tahsili-Fahadan, C Thomas, RJ Fallon, PW Kalivas and G Aston-Jones. 2014. Modafinil attenuates reinstatement of cocaine-seeking: Role for cystine-glutamate exchange and metabotropic glutamate receptors. *Addict Biol*, 19: 49-60. PMC3535502
313. Shen H, CD Gipson, M Huits and PW Kalivas. 2014. Prelimbic cortex and ventral tegmental area modulate synaptic plasticity in nucleus accumbens during cocaine-reinstated drug seeking. *Neuropsychopharmacology*, 39: 169-177. PMC3957111.
314. Pomierny-Chamiolo L, K Rup, B Pomierny, E Niedzielska, PW Kalivas and M Filip. 2014. Metabotropic glutamate receptors and their ligands in drug addiction. *Pharmacol Ther*, 142: 281-305. PMID 24362085
315. Reissner KJ, CD Gipson, LA Knackstedt, MD Scofield and PW Kalivas. 2014. Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. *Addict Biol*, 20: 316-23. PMC4437505
316. McClure EA, CD Gipson, RJ Malcolm, PW Kalivas and KM Gray. 2014. Potential role of N-acetylcysteine in the management of substance use disorder. *CNS Drugs*, 28: 95-106. PMC4009342
317. Smith ACW, YM Kupchik, MD Scofield, CD Gipson and PW Kalivas. 2014. Synaptic plasticity mediating cocaine relapse requires matrix metalloproteinases. *Nature Neuroscience*, 17: 1655-1657, 2014. PMC4241163
318. Kupchik YM, MS Scofield, KC Rice, K Cheng, BP Roques and PW Kalivas. 2014. Cocaine self-administration causes enduring opioid inhibition of GABAergic synaptic transmission and plasticity in ventral pallidum. *J Neuroscience*, 34: 1057-1066. PMC3891949
319. Gipson CD, YM Kupchik and PW Kalivas. 2014. Rapid, transient synaptic plasticity in addiction. *Neuropharmacology*, 76: 276-286. PMC3762905
320. McClure EA, NL Baker, CD Gipson, MJ Carpenter, A Roper, B Froeliger, PW Kalivas and KM Gray. 2015. An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. *Am J Drug Alcohol Abuse*, 41: 52-56. PMC4262740
321. Scofield MD, HA Boger, RJ Smith, PG Haydon and PW Kalivas. 2015. Gq-DREADD selectively initiates glial glutamate release and inhibits cue-induced cocaine seeking. *Biol Psychiat*, 78: 441-451. PMC4547911
322. Beckley JT, PK Randall, RJ Smith, PW Kalivas and JJ Woodward. 2015. Partial least squares discriminant analysis of nucleus accumbens core medium spiny neurons predicts phenotype and toluene sensitivity. *Addict Biol*, 21: 530-46. PMC4561223
323. Smith ACW, MD Scofield and PW Kalivas. 2015. The tetrapartite synapse: extracellular matrix remodeling contributes to corticoaccumbens plasticity underlying addiction. *Brain Res*, 1628: 29-39. PMC4589426

324. Roberts-Wolfe DJ and PW Kalivas. 2015. Glutamate transporter GLT-1 as a therapeutic target for substance use disorders. *CNS Neurol Disorders – Drug Targets*, 14: 745-756. PMC47330383
325. Kupchik YM, RM Brown, DJ Schwartz and PW Kalivas. 2015. Coding the direct and indirect pathways by D1 and D2 receptors is no valid for projections from the nucleus accumbens. *Nat Neuroscience*, 18: 1230-1232. PMC4551610
326. Froeliger B, PA McConnell, CD Gipson, N Stankeviciute, PW Kalivas and KM Gray. 2015. The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study. *Alc Drug Depend*, 156: 234-242. PMC4633320
327. Garcia-Keller C, Y Kupchik, D Roberts-Wolfe, C Gipson, N Stankeviciute, R Brown, LM Cancela and PW Kalivas. 2016. Glutamatergic mechanisms of comorbidity between stress disorders and cocaine addiction. *Mol Psychiatry*, 21:1063-1069. PMC4823171
328. Spencer, S, M Scofield and PW Kalivas. 2016. The good and bad news about glutamate in drug addiction. *J Psychopharmacol*, 30: 1095-1098. PMC5234332
329. Stefanik MT, YM Kupchik and PW Kalivas. 2016. Optogenetic inhibition of cortical afferents in the nucleus accumbens simultaneously prevents cue-induced transient synaptic potentiation and cocaine-seeking behavior. *Brain Struct Func*, 221: 1681-1689. PMC5259736
330. Scofield MD, H Li, B Siemsen, KL Healy, PK Tran, N Woronoff, HA Boger, PW Kalivas and KJ Reissner. 2016. Cocaine self-administration and extinction leads to reduced GFAP expression and morphometric features of astrocytes in the nucleus accumbens core. *Biol Psychiatry*, 80: 207-215. PMC4930433
331. Kalivas, PW and BC Kalivas. 2016. Corticostriatal circuitry in regulating diseases characterized by intrusive thinking. *Dial Clin Neuroscience*, 18: 65-76. PMC4826772
332. Moussawi, K, PW Kalivas and JW Lee. 2016. Abstinence from drug dependence after bilateral globus pallidus hypoxic ischemic injury. *Biol Psychiat*, 80: e79. PMC5238511
333. Scofield, MD, JA Heinsbroek, CD Gipson, YM Kupchik, S Spencer, AW Smith, D Roberts-Wolfe and PW Kalivas. 2016. The nucleus accumbens: Mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis. *Pharmacol Rev*, 68: 816-871. PMC4931870
334. Mulholland PJ, LJ Chandler and PW Kalivas. 2016. Signals from the 4th dimension regulate drug relapse. *Tr Neurosci*, 39: 472-485 PMC4930682
335. Augur, IF, AR Wycoff, G Aston-Jones, PW Kalivas and J Peters. 2016. Synthetic activation of ventromedial prefrontal cortex projection to the nucleus accumbens shell promotes extinction retrieval to reduce cocaine seeking. *J Neuroscience*, 36: 10174-80. PMC5039261
336. Brown RM*, YM Kupchik*, S Spencer, C Garcia-Keller, DJ Schwartz, KA Jordan, TC Jhou and PW Kalivas. 2017. Addiction-like synaptic impairments in obesity. *Biol Psychiatry*, 81: 797-806. PMC4889544

337. Back SE, JL McCauley, KJ Korte, DF Gros, V Leavitt, KM Gray, MB Hamner, SM DeSantis, R Malcolm, KT Brady and PW Kalivas. 2017. A double-blind randomized controlled pilot trial of N-acetylcysteine in Veterans with PTSD and substance use disorders. *J Clin Psychiatry*, 77: e1439-e1446. PMC5226873
338. Spencer, S, C Garcia-Keller, D Roberts-Wolfe, J Heinsbroek, M Mulvaney, A Sorrell and PW Kalivas. 2017. Cocaine reverses striatal plasticity produced during cocaine-seeking. *Biol Psychiat*, 81: 616-624. PMC5346331
339. Smith, ACW*, MD Scofield*, CD Gipson*, JA Heinsbroek*, D Neuhofer, DJ Roberts-Wolfe, S Spencer, NM Stankeviciute, R Smith, NP Allen, MR Lorang, WC Griffin III, HA Boger and PW Kalivas. 2017. Accumbens nNOS interneurons control cocaine relapse. *J Neuroscience*, 37: 742-756. PMC5296777
340. Heinsbroek, JA*, DN Neurohofer*, WC Griffin, GS Siegel, A-C Bobadilla, YM Kupchik+ and PW Kalivas+. 2017. Both D1- and D2-expressing accumbens-pallidal neurons regulate cocaine seeking. *J Neuroscience*, 37: 757-767. PMC5296778
341. Kupchik, YM and PW Kalivas. 2017. The direct and indirect pathways of the nucleus accumbens are not what you think. *Neuropsychopharmacol*, 42: 369-370. PMC5143491
342. Bobadilla, AC, C Garcia-Keller, JA Heinsbroek, M Scofield, V Chareunsouk, C Monforton and PW Kalivas. 2017. Accumbens mechanisms for cued sucrose-seeking. *Neuropsychopharmacol*, 42: 2377-2386. PMC5645741
343. Melis, M, R Frau, PW Kalivas, S Spencer, V Chioma, E Zamberletti, T Rubino and D Parolaro. 2017. New vistas on cannabis use disorder. *Neuropharmacol*, 124: 62-72, 2017. PMC5865400
344. Taniguchi, M MB Careira, YA Cooper, AC Bobadilla, JA Heinsbroek, N Koike, EB Larson, EA Balmuth, BW Hughes, RD Penrod, J Kumar, LN Smith, D Guzman, JS Takahashi, TK Kim, PW Kalivas, DW Self, Y Lin and CW Cowan. 2017. HDAC5 and its target gene, NPAS4, regulate cocaine addiction-related behaviors. *Neuron*, 96:130-144. PMC5761688
345. Spencer S and PW Kalivas. 2017. Glutamate transport: a new bench to bedside mechanism for treating drug abuse. *Intl J Neuropsychopharmacol*. 20: 797-812. PMC5632313
346. Spencer, S*, D Neuhofer*, V Chioma, C Garcia-Keller, D Schwartz, N Allen, M Scofield, T Ortiz-Ithier, PW Kalivas. 2018. A model of Δ^9 -tetrahydrocannabinol (THC) self-administration and reinstatement that alters synaptic plasticity in nucleus accumbens. *Biol Psychiat*, 84: 601-610. PMC6162175
347. Bobadilla AC, JA Heinsbroek, CD Gipson, WC Griffin, CD Fowler, PJ Kenny and PW Kalivas. 2017. Corticostriatal plasticity, neuronal ensembles and regulation of drug-seeking behavior. *Prog Brain Research*, 235: 93-112.
348. Bobadilla, A-C, C Garcia-Keller, V Chareunsouk, J Hyde, DM Camacho, JA Heinsbroek and PW Kalivas. 2018. Accubens brain-derived neurotrophic factor (BDNF) transmission inhibits cocaine seeking. *Addiction Biol*, in press.

349. Roberts-Wolfe D*, A-C Bobadilla*, JA Heinsbroek, D Neuhofler and PW Kalivas. 2018. Drug refraining and seeking potentiate synapses on distinct populations of accumbens medium spiny neurons. *J Neuroscience*, 38: 7100-7107. PMC6083453
350. Neuhofler D and PW Kalivas. 2018. Metaplasticity at the addicted tetrapartite synapse: A denominator of drug-induced adaptations and potential treatment target for addiction. 2018. *Neurobiol Learning Memory*, in press. PMC6112115
351. Parrilla-Carrero J, W Buchta, P Goswamee, O Culver, G McKendrick, B Harlan, A Moutal, R Penrod-Martin, A Lauer, V Ramakrishnan, R Khanna, PW Kalivas and A Riegel. 2018. Restoration of Kv7 channel mediated inhibition reduces cued-reinstatement of cocaine seeking. *J Neuroscience*, 38: 4212-4229. PMC5963852
352. Pardo-Garcia TR, C Garcia-Keller, T Penaloza, CT Richie, J Pickel, BT Hope, BK Harvey, PW Kalivas* and JA Heinsbroek*. 2018. Ventral pallidum is a primary target for accumbens D1 projections driving cocaine seeking. *J Neuroscience*, 39: 2041-2051. PMC6507080
353. Womersley, JS, D Townsend, PW Kalivas and J Uys. 2019. Targeting Redox regulation to treat substance use disorder using N-acetylcysteine. *Eur J Neuroscience*, 58: 2538-2551. PMC6387857
354. Garcia-Keller C, D Neuhofler, AC Bobadilla, S Spencer, V Chioma, C Monforton and PW Kalivas. 2019. Extracellular matrix signaling through $\beta 3$ integrin mediates cocaine cue-induced transient synaptic plasticity and relapse. *Biol Psychiatry*, 86: 377-387. PMC6697624
355. Kruyer, A, LE Ball, DM Townsend, PW Kalivas* and JD Uys*. 2019. Post-translational S-glutathionylation of cofilin increases actin cycling during cocaine seeking. *PLoS One*, 14: e0223037. PMC6759170
356. Kruyer, A, MD Scofield, D Wood, KJ Reissner and PW Kalivas. 2019. Heroin cue-evoked astrocytic structural plasticity at nucleus accumbens synapses inhibits heroin seeking. *Biol Psychiatry*, 86: 811-819. PMC6823145
357. Siemsen, BM, CM Reichel, KC Leong, C Garcia-Keller, CD Gipson, S Spencer, JA McFaddin, KN Hooker, PW Kalivas and MD Scofield. 2019. Effects of methamphetamine and self-administration and extinction on astrocyte structure and function in the nucleus accumbens core. *Neuroscience* 406: 528-541.
358. Kuhn, BN, PW Kalivas and AC Bobadilla. 2019. Understanding addiction using animal models. *Front Behav Neurosci*, 13: 262-272.
359. Roberts-Wolfe DJ, JA Heinsbroek, S Spencer, AC Bobadilla, ACW Smith and PW Kalivas. 2020. Transient synaptic potentiation in nucleus accumbens shell during refraining from cocaine seeking. *Addict Biol.*, 25: e12759
360. Neuhofler D, S Spencer, VC Chioma, LN Beloate, PW Kalivas. 2020. Cue presentation following cannabinoid self-administration transiently restores synaptic plasticity and is regulated by CB1 receptors. *Addict Biol.*, in press.

361. Kruyer, A, V Chioma and PW Kalivas. 2020. The opioid addicted tetrapartite synapse. *Biol Psychiatry*, 87: 34-43. PMC6898767
362. Buchta, WC, A Moutal, B Himes, C Garcia-Keller, ACW Smith, PW Kalivas, R Khanna and AC Riegel. 2020. *Mol Neurobiol*, 57: 346-357, PMC6980501
363. Heinsbroek, JA, A-C Bobadilla, E Dereschewitz, A Assali, RM Chalhoub, CW Cowan and PW Kalivas. 2020. Opposing regulation of cocaine seeking by glutamate and enkephalin neurons in the ventral pallidum. *Cell Reports*, 30: 2018-27, PMC7045305
364. Garcia-Keller, C, C Smiley, C Monforton, PW Kalivas* and J Gass*. 2020. N-acetylcysteine treatment during acute stress prevents stress-induced augmentation of addictive drug use and relapse. *Addict Biol*, in press.
365. Carter, JS, AM Kearns, KM Vollmer, C Garcia-Keller, RA Weber, NL Baker, PW Kalivas and CM Reichel. 2020. Long term impact of acute restraint stress on heroin self-administration, reinstatement and stress reactivity. *Psychopharmacol*, in press.
366. Garcia-Keller, C, MD Scofield, D Neuhofer, S Varanaxi, E Anderson, CT Richie, J Pickel, BT Hope, BK Harvey, CW Cowan and PW Kalivas. 2020. Relapse-associated transient synaptic plasticity requires integrin-mediated activation of focal adhesion kinase and cofilin. *J Neuroscience*, in press.
367. Price, W, H Moss, T Brown, PW Kalivas and D Jenkins. 2020. N-acetylcysteine mitigates acute opioid withdrawal behaviors and CNS oxidative stress in neonatal rats. *Pediatric Res*, in press.
368. Back, SE, K Gray, ES Ana, JL Jones, AM Jarnecke, JE Joseph, J Prisciandaro, T Killeen, DG Brown, L Taimina, E Compean, R Malcolm, JC Flanagan and PW Kalivas. 2020. N-acetylcysteine for the Treatment of Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder: Design and Methodology of a Randomized Clinical Trial, *Contemporary Clin Trials*, in press.
369. Garcia-Keller, C, T Penalzoza, L Belote, J Doolittle, B Froeliger and PW Kalivas. 2020. Synergism between varenicline and N-acetylcysteine promotes inhibition of nicotine use and seeking. *Behav Br Res*, submitted.
370. Bobadilla, A-C, E Dereschewitz, L Vaccaro, A Assali, JA Heinsbroek, M Scofield and PW Kalivas. 2020. Cocaine and sucrose seeking ensembles in the nucleus accumbens core. *Mol Psychiatry*, in revision.
371. Kruyer, A and PW Kalivas. 2020. Astrocytes as key cellular mediators of relapse. *Curr Op Pharmacology*, in revision.
372. Chalhoub, RM and PW Kalivas. 2020. Non-opioid Treatments for Opioid Dependence: Rationales and Data to Date. *CNS Neurol Disorders – Drug Targets*, in press
373. Kruyer, A and PW Kalivas. 2020. Heroin cues reveal astroblial subpopulations in nucleus accumbens core that decrease heroin seeking. *Biol Psychiatry*, submitted.

374. Neuhofer, D, C Garcia-Keller, K Seidling, LN Beloate, V Chioma, S Spencer and PW Kalivas. 2020. D9-tetrahydrocannabinol self-administration induces adaptation in the nucleus accumbens core that are cell-type specific. *Neuropsychopharmacology*, submitted.
375. Maier, A, A Dharan, G Oliver, M Berk, S Redston, SE Back, PW Kalivas, C Ng, R Antony and A Kanaan. 2020. A multi-centre, double blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol. *BMC Psychiatry*, in press.
376. Chioma, VC, A Kruyer, A-C Bobadilla, MD Scofield, A Angelis, Z Ellison and PW Kalivas. 2020. Heroin extinction and seeking induces cell specific matrix metalloproteinase activity in tetrapartite synapses. *Nature Neuroscience*, in press.

Invited Editorials and Commentaries

1. Kalivas, P.W. 1988. Where have all the peptides gone? *Brain and Behavioral Sciences*, (commentary).
2. Kalivas, P.W. 1995. Can EAA transmission play a ubiquitous role in drug-induced neural plasticity? *Behav. Pharmacol.* (commentary) 6: 1-3.
3. Kalivas, PW 2001. Drug addiction: To the cortex and beyond. *Am J Psychiatry* (Editorial), 158: 349-350.
4. Kalivas, PW. 2003. Predisposition to addiction: Pharmacokinetics, pharmacodynamics and brain circuitry. *Am J Psychiatry* (Editorial), 160: 1-3.
5. Kalivas PW. 2004. Choose to study choice in addiction. *Am J Psychiatry* (Editorial), 161: 193-194.
6. Melendez RI and PW Kalivas. 2004. Last call for adenosine transporters. *Nat Neuroscience* (News and Views) 7: 795-796.
7. Szumlinski, KK and PW Kalivas. 2004. Novel ideas about novelty. *Behav Pharmacol* (commentary) 15: 373-376.
8. Lavin, A and PW Kalivas. 2005. Clinical implications of cocaine-induced cortical depression. *Neuropsychopharmacol* (letter to editor), 5: 1034-1035.
9. Carr, D and PW Kalivas. 2006. Orexin: A gate-keeper of addiction. *Nat Medicine* (News and Views), 12: 274-76.
10. Kalivas PW and H Manji. 2008. Neuroplasticity in neuropsychiatric disease. *Neuropsychopharm Rev* (Editorial), 33: 2.
11. Lawrence A, P Beart and PW Kalivas. 2008. Neuropharmacology of addiction: Setting the scene. *Brit J Pharmacol* (Commentary), 154: 259-260. PMID: 18414384
12. Aston-Jones, G and PW Kalivas. 2008. Brain norepinephrine rediscovered in addiction research. *Biol Psychiat* (Commentary), 11: 1005-1006. PMID: 18482610

13. Carr, D and PW Kalivas. 2008. Confused about NMDA and addiction? Targeted knockouts provide answers and new questions. *Neuron (Preview)*, 59: 353-355. PMID: 18701061
14. Chandler, J and PW Kalivas. 2008. Brain's defense against cocaine. *Nature (News and Views)*, 455: 743-744. PMID: 18843354
15. Kalivas, PW. 2009. The manifest destiny of cocaine research. *Neuropsychopharmacol (Perspective)*, 34: 1089-1090. PMID: 19194378
16. Riegel, A and PW Kalivas. 2010. Lack of inhibition leads to abuse. *Nature (News and Views)*, 463: 743-744. PMID: PMC6451657
17. Kalivas PW and KT Brady. 2012. Hatching the addiction egg. *Nat Med (Bedside to Bench)*, 18: 502-503. PMID: 22481410
18. Scoffield, MD and PW Kalivas. 2013. Forgiving the sins of the father. *Nat Neuroscience (News and Views)*, 16: 4-5. PMID 23257926
19. Brown RM, YM Kupchik and PW Kalivas. 2013. The story of glutamate in drug addiction and of N-acetylcysteine as a potential pharmacotherapy. *JAMA Psychiatry (Viewpoint)*, 70: 895-897. PMID 23903770
20. Kalivas PW and CD Gipson. 2014. "Mourning" a lost opportunity. *Psychopharmacology (Commentary)*, 231: 3921-3922. PMID 24862367
21. Gipson CD and PW Kalivas. 2014. More Cocaine – More Glutamate – More Addiction. *Biol Psychiatry (Commentary)*, 76: 765-766. PMID 25442059
22. Kalivas PW. 2018. Deconstructing and reconstructing the dichotomy that is D1- and D2-expressing neurons. *Biol Psychiatry (Commentary)*, 84: 862-864. PMID 30466506
23. Kalivas PW and S Spencer. 2019. Reply to: N-acetylcysteine in treatment of substance use disorders. *Biol Psychiatry (Letter to Editor)*, 85, e61.
24. Neuhofer D and PW Kalivas. 2020. Understanding the munchies. *Neuron (Preview)*, in press.

Chapters and non-Refereed Papers

1. Kalivas, P.W., L.M. Halpern and A. Horita. 1978. Decrease in pentobarbital sleeping time by TRH: Characterization with power spectral analysis of EEG. *Proc. West. Pharmacol. Soc.* 21: 443-446.
2. Jennes, L., W.E. Stumpf, W.C. Beckman, P.W. Kalivas, C.B. Nemeroff and A.J. Prange, Jr. 1982. Topography and functional implications of neurotensin containing structures in the rat brain. *Ann. N.Y. Acad. Sci.* 400: 403-404.
3. Kalivas, P.W., C.B. Nemeroff and A.J. Prange, Jr. 1982. Neuroanatomical and neurochemical sites of action by neurotensin. *Ann. N.Y. Acad. Sci.* 400: 307-308.

4. Nemeroff, C.B., C.E. Hernandez, D. Luttinger, P.W. Kalivas and A.J. Prange. 1982. Neurotensin: A peptide with certain neuroleptic-like properties. *Proc. Third World Congress of Biol. Psychiat.*, 363-367. Elsevier, Amsterdam.
5. Nemeroff, C.B., C.E. Hernandez, D. Luttinger, P.W. Kalivas and A.J. Prange, Jr. 1982. Interactions of neurotensin with brain dopamine systems. *Ann. N.Y. Acad. Sci.* 400: 330-344.
6. Burgess, S.K., D. Luttinger, D.E. Hernandez, P.W. Kalivas, C.B. Nemeroff and A.J. Prange, Jr. 1983. Antagonism of the central nervous system effects of neurotensin by thyrotropin-releasing hormone. In *Thyrotropin-releasing Hormone*, ed. G.W. Bennett and E. Griffiths, 291-302. Raven Press, New York.
7. Kalivas, P.W., D.E. Hernandez, D. Luttinger, G. Bissette, G.A. Mason, C.B. Nemeroff and A.J. Prange, Jr. 1983. Neurotensin-induced hypothermia: Neuroanatomical and neurochemical mechanisms. In *Environment, Drugs and Thermoregulation*, ed. P. Lomax and E. Schonbaum, 108-112. Karger, Basel.
8. Kalivas, P.W. and A. Horita. 1983. Septohippocampal involvement in TRH antagonism of pentobarbital narcosis. In *Thyrotropin-releasing Hormone*, ed. G.W. Bennett and E. Griffiths, 283-290. Raven Press, New York.
9. Kalivas, P.W. 1984. Peptidergic modulation of the mesolimbic dopamine system. *Psychopharmacol. Bull.* 20: 354-357.
10. Nemeroff, C.B., P.W. Kalivas and A.J. Prange, Jr. 1984. Interaction of neurotensin and dopamine in limbic structures. In *Neurology and Neurobiology*, eds. E. Usdin, A. Carlsson, A. Dahlstrom and J. Engel. Alan R. Liss, Inc., New York. 8: 199-206.
11. Kalivas, P.W. 1985. Substance P modulation of the mesolimbic dopamine system. In *Endocoids*, ed. H. Lal, F. Lobella and J. Love. Alan R. Liss, New York. pp. 403-408.
12. Kalivas, P.W. 1986. Repeated administration with enkephalin into the A10 dopamine region produces supersensitivity of the mesolimbic dopamine system. In *Dopamine Systems and Their Regulation*, ed. G.N. Woodruff, J.A. Poat and P.J. Roberts, MacMillan Press, London. pp. 441-442.
13. Kalivas, P.W. 1986. Sensitization of mesolimbic dopamine neurons to opioids: A potential animal model of schizophrenia. *Proc. IVth World Congress of Biological Psychiatry*. Science Publishing Co., Inc., Elsevier, New York.
14. Kalivas, P.W. 1987. Behavioral and neurochemical sensitization to endogenous enkephalin and environmental stress: Role of the mesolimbic dopamine system. *Psychopharmacol. Bull.* 23: 415-416.
15. Dilts, R. and P.W. Kalivas. 1988. Localization of mu opioid and neurotensin receptors in the mesocorticolimbic dopamine system. *Ann. N.Y. Acad. Sci.* 537: 472-474.
16. Duffy, P. and P.W. Kalivas. 1988. Decreased release of endogenous dopamine in the A10 region in rats sensitized to cocaine and morphine. *Ann. N.Y. Acad. Sci.* 537: 475-477.
17. Dunn, A.J., E.M. Meyer and P.W. Kalivas. 1988. Hormonal modulation of neurotransmitter release. In *Presynaptic Regulation of Neurotransmitter Release: A Handbook*, ed. J. Feigenbaum. Plenum Press, New York.

18. Kalivas, P.W. and P. Duffy. 1988. Enkephalin modulation of the mesocorticolimbic dopamine system. *Ann. N.Y. Acad. Sci.* 537: 405-414.
19. Kalivas, P.W., P. Duffy, L.G. Lattimer and B. Weber. 1988. Sensitization of the mesocorticolimbic dopamine system by neuropeptides and stress: A role of the A10 dopamine neurons. In *Sensitization of the Nervous System*, ed. P.W. Kalivas and C.D. Barnes, 119-144. Telford Press, New Jersey.
20. Kalivas, P.W. and A.J. Prange, Jr. 1988. Control and peripheral actions of TRH. In *Peptide Hormones*, eds. A. Negro-Vilar and P.M. Conn. CRC Press, New York. Vol. 1: 165-193.
21. Steketee, J.D. and P.W. Kalivas. 1991. Sensitization to cocaine produced by injection of pertussis toxin into the A10 dopamine region. *NIDA Monogram*. 105: 545-546.
22. Kalivas, P.W., M. Klitenick., H. Hagler and M.C. Austin. 1991. The ventral pallidum: Involvement of the mesolimbic dopamine system. In: *The Basal Forebrain: Anatomy to Function*, ed. T.C. Napier, P.W. Kalivas, I. Hannin. Plenum Press, New York. pp. 315-326.
23. Churchill, L. and P.W. Kalivas. 1991. GABA and opioid receptor localization and adoption in the basal forebrain. In: *The Basal Forebrain: Anatomy to Function*, ed. T.C. Napier, P.W. Kalivas, I. Hannin. Plenum Press, New York. pp. 101-118.
24. Kalivas, P.W. and A.J. Bourdelais. 1991. Dialysis of GABA on the ventral pallidum: Modulation by dopamine. *Monitoring Molecules in Neuroscience*. Ed. H. Rollema, Bite Western K, WJ Drishout. pp 90-92.
25. Klitenick, M.A. and P.W. Kalivas. 1991. Somatodendritic release of dopamine in the A10 region is mediated by opioids and GABA. *Monitoring Molecules in Neuroscience*. pp 325-327.
26. Duffy, P. and P.W. Kalivas. 1991. Comparison between the release of dopamine in the VTA and ventral striatum in cocaine-sensitized rats. *Monitoring Molecules in Neuroscience*. pp. 413-414.
27. Kalivas, P.W. and J.D. Steketee. 1992. Second messenger systems involved in neurotensin stimulation of mesoaccumbens dopamine neurons. *Ann. N.Y. Acad. Sci.* 668: 157-164.
28. Kalivas, P.W. and J.D. Steketee. 1992. Possible transduction mechanisms mediating the acute and sensitized response to neurotensin in the ventral tegmental area. *Ann. N.Y. Acad. Sci.* 668: 157-164.
29. Kalivas, P.W., C. Striplin, J.D. Steketee, M.A. Klitenick and P. Duffy. 1992. Cellular mechanisms of behavioral sensitization to drugs of abuse. *Ann. N.Y. Acad. Sci.* 654: 128-137.
30. Kalivas, P.W., J.D. Steketee and P. Duffy. 1992. Mechanisms of cocaine-induced sensitization. *Clin. Neuropharm.*

31. Kalivas, P.W., L. Churchill and M.A. Klitenick. 1993. The function of feedback in limbic-motor circuitry. In: *Limbic Motor Circuits and Neuropsychiatry*, eds. P.W. Kalivas and C.D. Barnes. CRC Press, Boca Raton, FL. pp. 237-288.
32. Hooks, M.S. and P.W. Kalivas. 1994. Modeling individual susceptibility to substance abuse. In: *Strategies for Studying CNS Active Compounds*, ed. T. Palomo. Vol. 1, 303-318.
33. Kalivas, P.W. 1995. Neural basis of sensitization to cocaine. In: *The Neurobiology of Cocaine: Cellular and Molecular Mechanisms*, ed. R. Hammer, CRC Press, Boca Raton, FL. pp 81-98.
34. Sorg, B.A. and P.W. Kalivas. 1995. Stress and neuronal sensitization. In: *Neurobiological Consequences of Stress: Normal Adaptation to PTSD*, eds. M.J. Friedman, D.S. Charney and A.Y. Deutch, Raven Press, NY. pp 83-102.
35. Churchill, L. and P.W. Kalivas. 1996. Dopamine-opioid interactions in the basal forebrain. In: *Interaction Between Dopamine and Other Neurotransmitters in the Brain*. ed. C.R. Ashby, Jr., CRC Press, Boca Raton, FL. pg 55-66.
36. Kalivas, P.W. and Sorg, B.A. 1996. Role of neuropeptides and amino acids in the VTA in stress-induced activation of dopamine transmission. *NIAAA Monogram*, 29: 139-144.
37. Prasad, K., B.A. Sorg, C. Ulibarri and P.W. Kalivas. 1996. Cross-sensitization between stress and psychostimulants: role of mesocorticolimbic dopamine and HPA axis. *Ann. N.Y. Acad. Sci.*, 771: 617-625.
38. See, R.E. and P.W. Kalivas. 1996. Tolerance and sensitization to the effects of antipsychotic drugs on dopamine transmission. ed. J.G. Csernansky, Springer-Verlag Berlin, *Handbook of Experimental Pharmacology*, 120: 203-224.
39. Kalivas, P.W., L. Bush and G. Hanson. 1996. High and low behavioral response to novelty is associated with differences in neurotensin and substance P content. *Ann. N.Y. Acad. Sci.*, 780: 164-167.
40. Kalivas, P.W. and Sorg, B.A. 1996. Animal models of psychosis reveal involvement of hippocampal-corticostratial-mesencephalic circuitry. In *Dopamine Disease States.*, eds R.J. Beninger, T. Palomo, T. Archer, CYM Press, Madrid, pg. 463-476.
41. Kalivas, P.W. 1997. Commentary: Behaviorally relevant measures of glutamate transmission? Estimation of in vivo neurotransmitter. *Behav. Pharmacol.* 7: 658-660.
42. Pierce, R.C. and Kalivas, P.W. 1997. Locomotor behavior. *Current Protocols in Neuroscience*, ed J.N. Crawley, CRC Press.
43. Kalivas, P.W. 1998. Review of The Dopamine Receptors. *Quart. Rev. Biol.*, 73:123.
44. Churchill, L. and P.W. Kalivas. 1999. Opioid modulation of neurotransmitters and behavior. In: *Hormonal Modulation of Brain and Behavior*, ed. U. Halbreich. American Psychiatric Press, Inc.

45. Kalivas, P.W., L. Churchill and A. Romanides. 1999. Involvement of the pallidal-thalamocortical circuit in adaptive behavior. *Ann. NY Acad. Sci.*, 877: 64-70.
46. Cornish, J and Kalivas, P.W. 2000. A role for glutamate transmission in addiction to psychostimulants. *Addiction Biol.*, 5: 325-329.
47. Kalivas, PW 2000. Dopamine Systems. In: *The Corsini Encyclopedia of Psychology and Behavioral Science*, ed WE Craighead and CB Nemeroff, John Wiley & Sons.
48. Kalivas, PW 2002. The Circuitry of Addiction. In: *Neuropsychopharmacology: The Fifth Generation of Progress*. Eds. D Charney, J Coyle, K Davis, CB Nemeroff, Lippincott, Williams & Wilkins, 1357-1366.
49. Cornish JL and PW Kalivas. 2001. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. *J Addict Dis* 20: 43-54.
50. Baker, D.A., Cornish, J.L. and Kalivas, P.W. 2002 Glutamate and dopamine interactions in the motive circuit: implications for craving. In "*Glutamate and Addiction*", B.H. Herman, J. Frankenheim, R. Litten, P. Sheridan, and S.Zukin (Eds.), Humana Press, Totowa, NJ, 143-156.
51. McFarland, K and PW Kalivas. 2003. Motivational circuitry. In: *Handbook of Experimental Psychology. Vol 3, Biological Psychology*, M Gallagher, RJ Nelson eds, Plenum Press, NY. 379-404.
52. Kalivas, PW, K McFarland and RE See. 2003. Psychiatric pathophysiology: Addiction. In: "*Psychiatry, 2nd Edition*", A Tasman, J Kay, JA Lieberman (Eds), John Wiley & Sons, Ltd, Hoboken, NJ, 330-337.
53. Kalivas, PW. 2003. The development and expression of behavioral sensitization: Temporal profile of changes in gene expression. In "*Molecular Biology of Drug Addiction*", R Moldanado (Ed), Humana Press, Totowa, NJ, 161-172.
54. Kalivas, PW 2003. Neuroadaptations to psychostimulants used in treating ADHD. In "*Attention Deficit Hyperactivity Disorder: State of the Science; Best Practices*". P.S. Jensen & J. Cooper (Eds.). Kingston, NJ: Civic Research Institute. in press.
55. Kalivas, P.W., Toda, S., Bowers, M.S., Baker, D.A. and Ghasemzadeh, M.B. 2003. The temporal sequence of changes in gene expression by drugs of abuse, in *Drugs of Abuse: Neurological Reviews and Protocols*, Ed. Wang, J.Q., Humana Press, Totowa, New Jersey, 79: 3-11.
56. Kalivas, PW, K McFarland and RE See. 2003. Neuropathology of addiction, in *Psychiatry*, A Tasman, J Kay, JA Lieberman, Eds, WB Saunders Co, Philadelphia, PA, Vol., pg 330-37.
57. Crespo, JA, Crespo, JM Oliva, MB Ghasemzadeh, PW Kalivas and E Ambrosio. 2002. Neuroadaptive changes in NMDAR1 gene expression after extinction of cocaine self-administration". *Ann. N. Y. Acad. Sci.* 965: 78-91.
58. Kalivas, PW. 2004. Neuronal circuitry and cellular physiology mediating the reinstatement of drug seeking. In, *Neuroscience of Drug Addiction: Focus on Neural Plasticity*, M Massotti and L Pulvirenti, eds., Istituto Superiore di Sanita, Roma, IT, Rapporti ISTISAN, 03/7.

59. Baker DA and PW Kalivas. 2003. Sensitization and relapse: dopamine glutamate interactions. In, *Dopamine and Glutamate in Psychiatric Disorders*, Eds Maarten Reith and Werner J Schmidt. Humana Press Inc.
60. Kalivas PW, K McFarland, MS Bowers, K Szumlinski, ZX Xi and DA Baker. 2003. Glutamate transmission and addiction to cocaine. *Ann NY Acad Sci* 1003: 169-175.
61. Baker DA, McFarland K, Lake RW, Shen H, Toda, S, and PW Kalivas. 2003. N-Acetyl cysteine-induced blockade of cocaine-induced reinstatement. *Ann. N.Y. Acad. Sci.* 1003: 349-351.
62. Bowers MS, Lake RW, McFarland K, Peterson YK, Lanier SM, Lapish CC, and PW Kalivas. 2003. AGS3: A G-protein regulator of addiction-associated behaviors. *Ann. N.Y. Acad. Sci.* 1003: 356-357.
63. Ghasemzadeh MB, Permenter LK, Lake RW, and PW Kalivas. 2003. Nucleus accumbens Homer proteins regulate behavioral sensitization to cocaine. *Ann. N.Y. Acad. Sci.* 1003: 395-397.
64. Bowers MS, Lake RW, Rubinchik S, Dong J-Y, and PW Kalivas. 2003. Elucidation of Homer 1a function in the nucleus accumbens using adenovirus gene transfer technology. *Ann. N.Y. Acad. Sci.* 1003: 419-421.
65. Melendez R and PW Kalivas. 2003. Metabotropic glutamate receptor regulation of extracellular glutamate levels in the prefrontal cortex. *Ann. N.Y. Acad. Sci.* 1003: 443-444.
66. Moran MM, Melendez R, Baker D, Kalivas PW, and JK Seamans. 2003. Cystine/glutamate antiporter regulation of vesicular glutamate release. *Ann. N.Y. Acad. Sci.* 1003: 445-447.
67. Szumlinski KK, Toda S, Middaugh LD, Worley PF, and PW Kalivas. 2003. Evidence for a relationship between Group 1 mGluR hypofunction and increased cocaine and ethanol sensitivity in Homer2 null mutant mice. *Ann. N.Y. Acad. Sci.* 1003: 468-471.
68. Tang X-C, and PW Kalivas. 2003. Bidirectional modulation of cystine/glutamate exchanger activity in cultured cortical astrocytes. *Ann. N.Y. Acad. Sci.* 1003: 472-475.
69. Kalivas, PW. 2006. New directions in pharmacotherapy for addiction, or can we forget to be addicted. *Clin Neuroscience Res*, in press.
70. Baker, DA and PW Kalivas. 2006. The significance of glutamate in microdialysates. In *Handbook of Microdialysis: Methods, applications and perspective*, Eds BHJ Westerink and Cremers, pg 33-46.
71. Kalivas, PW and LM Cancela. 2006. Hipotesis etiopatogenicas de los trastornos por abuso de sustancias. In, *Historia de la Psicofarmacologia*. Eds, F Lopez-Munoz and CA Gonzalez, pg 567-574.
72. Toda, S and PW Kalivas. 2007. Research in addiction as chronic and progressive mental disorder involving metaplasticity. *Cell Biol*, 26: 2-7.
73. Knackstedt LA and PW Kalivas. 2006. Pharmacotherapeutic targets for regulating cocaine-induced plasticity. *Drugs of the Future*, 31: 893-900.

74. Kalivas PW, J Peters and L Knackstedt. 2006. Animal models and brain circuits in drug addiction. *Mol Interventions* 6: 339-344.
75. LaLumiere RT and PW Kalivas. 2007. Reward and drugs of abuse. In, *Neurobiology of Learning and Memory*, Eds, RP Kesner and JL Martinez, Academic Press, pp 459-482.
76. Melendez, R and PW Kalivas. 2008. Basic science of addiction. In, *Pain and Chemical Dependency*, Eds, H Smith and S Passik, Oxford Univ Press, pg 31-38.
77. Mohan A, S Pendyam, G Li, J Gall, PW Kalivas and SS Nair. 2008. Computational models of neuronal networks- Modeling neuroplasticity in glutamate transmission due to cocaine. In, *New Research on Neuronal Networks*, Ed. Fran Columbus, Nova Science Publishers, NY, pg 65-107.
78. Kalivas PW. 2008. Glutamate. In, *Encyclopedia of Drugs, Alcohol & Addictive Behavior*, Eds P Korsmeyer and HR Kranzler, Macmillan Reference, USA, Ed 3.
79. Kalivas PW. 2008. Brain structures and drugs. In, *Encyclopedia of Drugs, Alcohol & Addictive Behavior*, Eds P Korsmeyer and HR Kranzler, Macmillan Reference, USA, Ed 3.
80. Torregrossa MM and PW Kalivas. 2009. Addictive processes. In, *Handbook of Neuroscience for Behavioral Scientists*, Eds Gary G Berntson and John T Cacioppo, John Wiley and Sons, NY
81. See RE and PW Kalivas. 2009. Neuroscience of substance abuse and dependence. In: Kaplan & Sadock's *Comprehensive Textbook of Psychiatry*, Eds. Sadock BJ, Sadock VA, Ruiz P, 9th edition, Lippincott Williams & Wilkins.
82. Olive MF and PW Kalivas. 2009. Conditioning in addiction. In: *Addiction Medicine*, Ed BA Johnson, Springer, New York.
83. Pierce RC and PW Kalivas. 2009. Locomotor behavior. *Curr Protoc Neurosci*, Chap 8, Unit 8.1. PMID: 18428664
84. Uys J and PW Kalivas. 2009. Cocaine Dependence. *Encyclopedia of Pharmacol*, Ed. Ian Stoleman, Springer-Verlag, New York.
85. Reissner KJ and PW Kalivas. 2010. Neurobiology of Substance Abuse Disorders. In: *Pediatric Psychopharmacology, 2nd Edition*. Chapter 17 pp 237-247. Oxford University Press.
86. LaLumiere, RT and PW Kalivas. 2010). Drug Priming. In Koob, G, Le Moal, M, and Thompson, R. (eds). *Encyclopedia of Behavioral Neuroscience*. Academic Press, p. 431-436.
87. Gipson, CD and PW Kalivas. 2011. Pharmacotherapies in drug addiction. In: *Drug Discovery for Psychiatric Disorders*. Rankovic, Z., Bingham, M., Hargreaves, R., & Nestler, E. (Eds). Royal Society of Chemistry.
88. Gipson, CD and PW Kalivas. 2011. Neural Basis of Drug Addiction. In: *Neurobiology of Drug Abuse in Adolescents*, São Paulo, Brazil.
89. Reissner KJ and PW Kalivas. 2012. Common Mechanisms of Addiction. In: *Encyclopedia of Addictive Behaviors*. Chapter 141, Academic Press.

90. LaLumiere RT and PW Kalivas. 2012. Motivational Systems: Rewards and Incentive Value. In Weiner, I. (ed). *Handbook of Psychology (2nd ed.)*. Volume 3: Biological Psychology and Neuroscience. (Vol. 3 eds: Nelson, R., and Mizumori, S.). Wiley.
91. Reid AG, AR Lingford-Hughes, L Cancela and PW Kalivas. 2012. Substance abuse disorders. In: *Handbook of Clinical Neurology*, Vol. 106, *Neurobiology of Psychiatric Disorders*. Eds TE Schlaepfer and CB Nemeroff, Elsevier, p. 419-431.
92. Reissner KJ and PW Kalivas. 2012. Cellular and molecular mechanisms of addiction. In: *Neurobiology of Mental Illness*, 4th Ed, Oxford University Press. Eds D Charney, EJ Nestler.
93. Scofield MD, JD Uys and PW Kalivas. 2014. Cocaine Dependence. In: *Encyclopedia of Psychopharmacology*, Springer Essay, pp 1-6.
94. Reissner KJ and PW Kalivas. 2014. Emerging roles for glial pathology in addiction. In: *Pathological Potential for Neuroglia: Possible New Targets for Medical Intervention*. Eds. Vladimir Parpura and Alexei Verkhratsky, Springer, Chap 17, p. 397-419.
95. Moran R, KE Stephan, M Botvinick, M Breakspear, CS Carter, PW Kalivas, PR Montague, MP Paulus and F Petzscner. 2016. Candidate examples for a computational approach to address practical problems in psychiatry. In: *Computational Psychiatry: New Perspectives on Mental Illness*, edited by A. D. Redish and J. A. Gordon. Strüngmann Forum Reports, vol. 20, J. Lupp, series editor. Cambridge, MA: MIT Press, pg 223-245.
96. KJ Reissner and PW Kalivas. 2017. Cellular and Molecular Mechanisms of Addiction. In: *Neurobiology of Mental Illness*, 5th Edition. Oxford University Press. Chapter 46
97. R Philpot and PW Kalivas, 2019, Ch 24: Illicit Compounds and Substance Use Disorder, In: *Brody's Human Pharmacology*, 6th Edition, Elsevier, pg 202-214
98. Beloate LN and PW Kalivas, 2018, Role of the extracellular matrix in addiction. In: *Neural Mechanisms of Addiction*, editor M Torregrossa, Elsevier, in press